CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 1 of 112 TITLE PAGE  
Protocol Title:  
A Phase III, Open-label, Randomized, Controlled, M ulti-country Study to E valuate the 
Immune Response, Safety and R eactogenicity of RSVPreF3 OA Investigational V accine 
When Co- administered with 20 -Valent P neumococcal Conjugate Vaccine (PCV20) in Adults 
Aged 60 Y ears and O lder. 
Protocol Number:  219276 
Compound:  RSVPreF3 OA  
Study Phase:  III 
Sponsor Name:  GlaxoSmithKline Biologicals S.A.  
Legal Registered Address:  Rue De L'institut 89, 1330 Rixensart, Belgium 
EU CT  Number : 2022-501988-40-00 
Date of Original Protocol: 06 January 2023 
Date of Original Protocol v2.0:  27 February 2023 
Date of Protocol Amendment v1.0:  23 June 2023 
C O N FI D E N TI A L  2 1 9 2 7 6 (R S V O A = A DJ -0 1 9 ) 
A me n d me nt v 1. 0   
 
2 3-J u ne- 2 0 2 3 2 of 1 1 2 A p pr o v al D ate:  2 3-J u ne- 2 0 2 3 
S p o ns or Si g nat or y 
  
Na dia Me yer , M D Cli nical Pr oject Lea d  
R S V Ol der A d ults  
  Date  
 Me dical M o nit or n a me a n d co ntact i nf or mati o n will be pr o vi de d se par atel y.    P P D
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 3 of 112 Protocol Investigator Agreement  
I agree:  
• To conduct the study in compliance with this protocol, any future protocol 
amendments or protocol administrative changes, with the terms of the clinical trial agreement and with any other study conduct procedures and/or study conduct documents provided by GlaxoSmithKline (GSK) Biologicals SA. 
• To assume responsibility for the proper conduct of the study at this site. 
• That I am aware of, and will comply with, ‘Good Clinical Practice’ (GCP) and all applicable regulatory requirements.  
• That I will comply with the terms of the site agreement.  
• To ensure that all individuals assisting me with the study are adequately informed about the GSK study intervention and other st udy-related duties and functions as 
described in the protocol. 
• To supervise any individual or party to whom I have delegated study-related duties and functions conducted at the study site. 
• To ensure that any individual or party to whom I have delegated study-related duties and functions conducted at the study site are qualified to perform those study- related 
duties and functions.  
• To acquire the reference ranges for laboratory tests performed locally and, if required by local regulations, obtain the laboratory’s current certification or Quality Assurance procedure manual. 
• To ensure that no clinical samples (including blood and serum samples) are retained onsite or elsewhere without the approval of GSK and the express written informed consent of the participant.  
• To perform no biological assays on the clinical samples other than those described in the protocol or its amendment(s).  
• To co -operate with representative(s) of GSK in the monitoring process of the study 
and in resolution of queries about the data. 
• To have control of all essential documents and records generated under my responsibility before, during, and after the study. 
• That I have been informed that certain regulatory authorities require the sponsor to obtain and supply, as necessary, details about the investigator’s ownership interest in the sponsor or the investigational intervention(s), and more generally about his/her financial ties with the sponsor. GSK will use and disclose the information solely for the purpose of complying with regulatory requir ements.  
Hence, I:  
• Agree to supply GSK with any necessary information regarding ownership interest and financial ties (including those of my spouse and dependent children).  
• Agree to promptly update this information if any relevant changes occur during the study and for 1 year following completion of the study. 
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 4 of 112 • Agree that GSK may disclose any information about such ownership interests and 
financial ties to regulatory authorities.  
• Agree to provide GSK with an updated Curriculum Vitae and all other documen ts 
required by regulatory agencies for this study.  
 
Investigator name:   __________________________________________ 
 
Signature:    __________________________________________ 
 Date:     __________________________________________ 
 
 
 
  
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 5 of 112 PROTOCOL SUMMARY OF CHANGES TABLE  
 
DOCUMENT HISTORY    
Document  Date Substantial  Region  
Amendment 1.0  23-June -2023  Yes Global  
Original Protocol v2.0  27-February -2023  No Global  
Original Protocol  06-January -2023  - - 
Amendment v1.0 (23- June-2023) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
Overall Rationale for Protocol Update: 
The protocol has been  amended to include the definition of Serious A dverse R eaction 
(SAR) /Suspected Unexpected Serious Adverse Reactions (SUSAR) , and to clarify t ime period 
for collecting AE, SAE, and pIMD i nformation  as required in Request for I nformation from 
Belgium member state of the European Medicines Agency dated 14-June-2023. 
(Added text is bold italic , delet ed text is strikethrough ) 
Section # and Name  Description of Change  Brief Rationale  
8.3.1 Time Period and 
Frequency for Collecting 
AE, SAE, and pIMD Information Edited  text: 
All AEs (regardless of the assessment of relatedness to the study vaccines), including  all 
SAEs and all pIMDs will be collected from the first study intervention administration. All 
SAEs a nd all pIMDs will be 
collected until 6 months after the 
last study intervention 
administration at the timepoints 
specified in the SoA (Section 1.3 ). 
AEs (including SAEs and 
pIMDs)  leading to withdrawal 
from the study will be collected 
from the time of the first study 
intervention administration until 
the participant is discharged from the study.  
In addition, SAEs assessed as 
related to study participa tion (e.g., Clarification  
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 6 of 112 protocol -mandated invasive 
procedures)  or related to any 
other GSK product (non -IMP) 
will be recorded from the time a 
participant consents to participate in the study until the participant is discharged from the study.  
 
Deleted text: 
All SAEs and pIMDs will be 
collected from the start of study 
intervention until 6 months after 
the last administration of study 
interventions at the time points 
specified in the SoA (Section 1.3).   
SAEs assessed as related to study 
participation (e.g., st udy 
intervention, protocol mandated 
procedures, invasive tests, or 
change in existing therapy) or 
related to a GSK product 
(non IMP) will be recorded from 
the time a participant consents to 
participate in the study until the 
participant is discharged from the 
study.  
All AEs/SAEs/pIMDs leading to 
withdrawal from the study will be 
collected and recorded from the 
time of the first receipt of study 
intervention until the participant is 
discharged from the study.  
 
10.4 Appendix 4: 
Abbreviations and Glossary of Terms  Added to Abbreviation s and 
Glossary of Terms list : 
Serious Adverse Reaction : 
Suspected Unexpected Serious Adverse Reactions : All noxious 
and unintended responses to an investigational medicinal product  
(IMP) related to a ny dose 
administered that result in death, are life -threatening, require patient 
hospitalization or prolongation of 
existing hospitalization, result in 
persistent or significant disability or incapacity, or are a congenital anomaly or birth defect.   
Suspected Unexpected Serious 
Adverse Reactions: A Suspected 
Unexpected Serious Adverse Required  in Request for I nformation from 
Belgium , EMA  
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 7 of 112 Reaction is a Serious Adverse 
Reaction whose nature, severity or 
outcome is not consistent with the reference safety information.  
 
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 8 of 112 TABLE OF CONTENTS  
1.0 PROTOCOL SUMMARY  ........................................................................................ 13  
1.1 Synopsis  .......................................................................................................... 13  
1.2 Schema  ............................................................................................................ 16  
1.3 Schedule of Activities  .................................................................................... 17  
2.0 INTRODUCTION  ..................................................................................................... 24  
2.1 Study Rationale  .............................................................................................. 24  
2.2 Back ground .................................................................................................... 24  
2.3 Benefit/Risk Assessment  ............................................................................... 25  
2.3.1  Risk Assessment  ................................................................................ 25  
2.3.2  Benefit Assessment  ........................................................................... 26  
2.3.3  Overall Benefit -Risk Conclusion ...................................................... 26  
3.0 OBJECTIVES, ENDPOINTS, AND ESTIMANDS  ............................................... 27  
4.0 STUDY DESIGN ....................................................................................................... 29  
4.1 Overall Design  ................................................................................................ 29  
4.1.1  Overview of the Recruitment Plan  .................................................... 30  
4.1.2  Enrollment Rules  ............................................................................... 30  
4.2 Scientific Rationale for Study Design  .......................................................... 30  
4.3 Justification for Dose  ..................................................................................... 31  
4.4 End of Study Definition  ................................................................................. 32  
4.5 Study Stopping Criteria  ................................................................................ 32  
4.6 Participant Input into Design  ....................................................................... 32  
5.0 STUDY POPULATION ............................................................................................ 33  
5.1 Inclusion Criteria  ........................................................................................... 33  
5.2 Exclusion Criteria  .......................................................................................... 33  
5.2.1  Medical Conditions ........................................................................... 33  
5.2.2  Prior and Concomitant Therapy ........................................................ 34  
5.2.3  Prior/Concurrent Clinical Study Experience  ..................................... 35  
5.2.4  Other Exclusions ............................................................................... 36  
5.3 Caregiver Support  ......................................................................................... 36  
5.4 Lifestyle Considerations  ................................................................................ 36  
5.5 Screen Failures ............................................................................................... 36  
5.6 Criteria for Temporarily Delaying  .............................................................. 37  
6.0 STUDY INTERVENTION(S) AND CONCOMITANT THERAPY  .................... 39  
6.1 Study Interventions Administered  ............................................................... 40  
6.1.1  Medical Devices  ................................................................................ 41  
6.2 Preparation, Handling, Storage, and Accountability ................................. 41  
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 9 of 112 6.3 Measures to Minimize Bias: Randomization and Blinding  ....................... 41  
6.3.1  Participation Identification  ................................................................ 41  
6.3.2  Randomization to Study Intervention ............................................... 42  
6.3.3  Intervention Allocation to the Participant ......................................... 42  
6.3.4  Allocation of Participants to Assay Subsets  ...................................... 42  
6.3.5  Blinding and Unblinding ................................................................... 43  
6.4 Study Intervention Compliance  ................................................................... 43  
6.5 Dose Modification .......................................................................................... 43  
6.6 Treatment of Overdose ................................................................................. 43  
6.7 Concomitant Therapy  ................................................................................... 43  
7.0 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL ................................... 45  
7.1 Discontinuation of Study Intervention ........................................................ 45  
7.1.1  Contraindications to Subsequent Study Intervention Administration  ................................................................................... 45
 
7.2 Participant Discontinuation/Withdrawal from the Study  ......................... 46  
7.3 Lost to Follow- up ........................................................................................... 47  
8.0 STUDY ASSESSMENTS AND PROCEDURES  .................................................... 48  
8.1 Immunogenicity Assessments  ....................................................................... 49  
8.1.1  Biological Samples  ............................................................................ 50  
8.1.2  Laboratory Assays ............................................................................. 50  
8.1.3  Immunological Read -Outs  ................................................................ 51  
8.1.4  Immunological Correlates of Protection  ........................................... 56  
8.2 Safety Assessments  ........................................................................................ 56  
8.2.1  Pre-Vaccination Procedures .............................................................. 56  
8.2.2  Safety Contact at 6 Months Post- Last Vaccination  ........................... 58  
8.2.3  Clinical Safety Laboratory Tests  ....................................................... 58  
8.3 Adverse Events, Serious Adverse Events, and Other Safety Reporting  ........................................................................................................ 58
 
8.3.1  Time Period and Frequency for Collecting AE, SAE, and pIMD Information  ............................................................................. 59
 
8.3.2  Method of Detecting AEs, SAEs, and pIMDs .................................. 62  
8.3.3  Follow-up of AEs, SAEs, and pIMDs ............................................... 62  
8.3.4  Regulatory Reporting Requirements for SAEs and Other Events ................................................................................................ 62
 
8.3.5  Treatment of Adverse Events  ............................................................ 63  
8.3.6  Medical Device Deficiencies  ............................................................ 63  
8.4 Participant Card  ............................................................................................ 64  
8.5 Pharmacokinetics  .......................................................................................... 65  
8.6 Phar macodynamics ....................................................................................... 65  
8.7 Genetics  .......................................................................................................... 65  
8.8 Biomarkers  ..................................................................................................... 65  
8.9 Immunogeni city Assessments  ....................................................................... 65  
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 10 of 112 8.10  Health Outcomes  ........................................................................................... 65  
8.11  Health Economics  .......................................................................................... 65  
9.0 STATISTICAL CONSIDERATIONS  ..................................................................... 66  
9.1 Statistical Hypotheses  .................................................................................... 66  
9.2 Populations for Analysis ............................................................................... 67  
9.2.1  Criteria for Elimination  ..................................................................... 67  
9.3 Statistical Analyses  ........................................................................................ 67  
9.3.1  Primary Endpoint(s)/Estimand(s) Analysis  ....................................... 68  
9.3.2  Secondary Endpoint(s)/Estimand(s) Analysis  ................................... 69  
9.4 Interim Analysis  ............................................................................................. 70  
9.4.1  Sequence of Analysis ........................................................................ 70  
9.5 Sample Size Determination  ........................................................................... 70  
10.0  SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ................................................................................................. 73  
10.1  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  ............................................................................................... 73
 
10.1.1  Regulatory and Ethical Considerations  ............................................. 73  
10.1.2  Adequate Resources  .......................................................................... 74  
10.1.3  Financial Disclosure  .......................................................................... 74  
10.1.4  Recruitment Arrangements and Informed Consent Process  ............. 74  
10.1.5  Data Protection  .................................................................................. 75  
10.1.6  Committees Structure  ........................................................................ 76  
10.1.7  Dissemination of Clinical Study Data  ............................................... 76  
10.1.8  Data Quality Assurance  ..................................................................... 77  
10.1.9  Source Documents ............................................................................ 77  
10.1.10  Study and Site Start and Closure ....................................................... 78  
10.1.11  Publication Policy  ............................................................................. 79  
10.2  Appendix 2: Clinical Laboratory Tests  ....................................................... 80  
10.3  Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, Follow- up, and Reporting for Study 
Intervention  .................................................................................................... 81
 
10.3.1  Definition of AE  ................................................................................ 81  
10.3.2  Definition of SAE and Serious Adverse Device Effect (SADE)  .............................................................................................. 84
 
10.3.3  Adverse Events of Special Interest  ................................................... 85  
10.3.4  Clinical Laboratory Parameters and Other Abnormal Assessments Qualifying as AEs or SAEs ......................................... 96
 
10.3.5  Recording and Follow-Up of AEs, SAEs, pIMDs, and/or Device Deficiencies  .......................................................................... 96
 
10.3.6  Reporting of SAEs, pIMDs, Medical Device SAEs ....................... 101  
10.4  Appendix 4: Abbreviations and Glossary of Terms ................................. 103  
10.5  Appendix 5: Protocol Amendment History  ............................................... 109  
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 11 of 112 11.0  REFERENCES  ........................................................................................................ 111  
 
CONFIDENTIAL 219276 (RSV OA=ADJ-019)
Amendment v1.0
 
23-June-2023 12 of 112 LIST OF TABLES 
Table 1  Schedule of Activities for the Co-ad Group ..................................................... 17  
Table 2  Schedule of Activities for the Control Group ................................................... 20  
Table 3  Interval Between Study Visits (Co-ad Group) ................................................. 23  
Table 4  Interval Between Study Visits (Control Group) ............................................... 23  
Table 5  Study Interventions Administered .................................................................... 40  
Table 6  Biological Samples ........................................................................................... 50  
Table 7  Laboratory Assays ............................................................................................ 50  
Table 8  Immunological Read-outs ................................................................................ 51  
Table 9  Timeframes for Collection and Reporting of Safety Information                           
for the Co-ad Group .......................................................................................... 60  
Table 10  Timeframes for collection and Reporting of Safety Information                       
for the Control Group ....................................................................................... 61  
Table 11  Timeframes for Submitting SAE and Other Events Reports to IQVIA ........... 63  
Table 12  Study Objectives and Null Hypothesis ............................................................. 66  
Table 13  Analysis Sets .................................................................................................... 67  
Table 14  Overall power to demonstrate primary objectives: non-inferiority                     
of the immunogenicity of RSVPreF3 OA investigational vaccine when                     
co-administered with pneumococcal vaccine (PCV20) as compared to when 
administered alone- assuming 490 evaluable participants in each group ......... 71  
Table 15  Solicited Administration Site Events ................................................................ 82  
Table 16  Solicited Systemic Events ................................................................................ 82  
Table 17  List of Potential Immune-Mediated Diseases (pIMDs) .................................... 86  
Table 18  Intensity Scales for Solicited Events ................................................................ 98  
Table 19  Abbreviations List .......................................................................................... 103  
Table 20  Glossary of Terms .......................................................................................... 105  
 
LIST OF FIGURES 
Figure 1  Study Design Overview  .................................................................................. 16  
 
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0  
23-June-2023 13 of 112 1.0 PROTOCOL SUMMARY 
1.1 Synopsis  
Protocol Title:  
A Phase III, open- label, randomized, controlled, multi -country study to evaluate the immune 
response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when 
co-administered with 20- valent pneumococcal conjugate vaccine (PCV20) in adults aged 
60 years and older.  
Rationale : 
GlaxoSmithKline Biologicals SA (GSK) is developing a new respiratory syncytial virus 
(RSV) PreFusion protein 3 Older Adult (OA) investigational vaccine (RSVPreF3 OA) against 
RSV- associated (subtypes A and B) disease in adults ≥60 years of age (YOA). The va ccine 
development is currently in Phase III, and immunogenicity, safety, and reactogenicity of the 
candidate vaccine when co -administered with other vaccines are being investigated.  
Like RSV, pneumococcal disease also presents high disease burden among older adults and 
the seasonality of RSV disease and invasive pneumococcal disease is similar.   
The present study will assess the immunogenicity, safety and reactogenicity of the RSVPreF3 
OA investigational vaccine when co- administered with  the 20 valent pneum ococcal  conjugate 
vaccine (referred to as Prevnar 20 in USA or Apexxnar in Europe [hereafter referred to as 
PCV20 ]) in adults ≥60 YOA.   
Objectives, Endpoints, and Estimands: 
Objectives  Endpoints and Estimands  
Primary * 
•To demonstrate the non- inferiority of
PCV20 when co -administered with the
RSVPreF3 OA investigational vaccine
compared to PCV20 administered alone•Opsonophagocytic (OP) antibody (Ab)
titers for each of the pneumococcal
vaccine serotype (ST) expressed asbetween groups geomet ric mean titer
(GMT) ratio, 1 month after the PCV20dose
•To demonstrate the non -inferiority of
RSVPreF3 OA  investigational vaccine
in terms on RSV -A neutrali zation
antibodies  when co -administered with
PCV20 compared to RSVPreF3 OAinvestigational vaccine administeredalone•RSV -A neutralizing Ab titers expressed as
between groups GMT ratio, 1 month afterthe RSVPreF3 OA investigational vaccinedose
•To demonstrate the non -inferiority of
RSVPreF3 OA investigational vaccinein terms of RSV -B neutralization
antibodies when co- administered with
the PCV20 vaccine compared to
RSVPreF3 OA investigational vaccineadministered alone.•RSV -B neutralizing Ab titers expressed as
between groups GMT ratio, 1 month afterthe RSVPreF3 OA inves tigational vaccine
dose
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0  
23-June-2023 14 of 112 Objectives  Endpoints and Estimands  
Secondary  
•To evaluate the humoral immune
response to RSVPreF3 OAinvestigational vaccine when
co-administered with the PCV20 or
administered alone•RSV -A neutralizing Ab titers expressed as
mean geometric increase (MGI) over
baseline at 1 month after the RSVPreF3OA investigational vaccine dose
•RSV -B neutralizing Ab titers expressed as
MGI over baseline at 1 month after theRSVPreF3 OA investigational vaccinedose
•To evaluate the safety and reactogenicity
following administr ation of the
RSVPreF3 OA investigational vaccine
and PCV20, co -administered or
administered alone.•Percentage of participants reporting each
solicited event with onset within 7 days
after vaccine administration ( i.e., the day
of vaccination and 6 subsequent days)
•Percentage of participants reporting
unsolicited AE within 3 0 days after
vaccine administration ( i.e., the day of
vaccination and 29 subsequent days)
•Percentage of participants reporting SAEs
after vaccine administration (Day 1) up to
EoS (6 months  after last vaccination)
•Percentage of participants reporting
pIMDs after vaccine administration (Day
1) up to EoS (6 months after last
vaccination)
Abbreviations: Ab=antibody; AE=adverse event; EoS=end of study; GMT=geometric mean titer; MGI=mean 
geomet ric increase; OA=older adult; OP=opsonophagocytic; PCV 20=20-valent pneumococcal vaccine; 
pIMD=potential  immune -mediated disea se; RSV=respiratory syncytial virus ; RSVPreF3 OA=respiratory 
syncytial virus PreFusion protein 3 older adult investigational vaccin e; SAE=serious adverse event; 
ST=serotype.   
* PCV and RSV-A endpoint will be assessed as co -primary and following the current success RSV -B will be
demonstrated as sequential. Refer to  Section 9.3.1.1  for the testing sequence of primary objectives.
Overall Design: 
Experimental design : Phase III, open-label, randomized, controlled, multi-country study with 
2 parallel groups.  Study groups and Randomization: Approximately 1090 eligible participants will be 
randomly (1:1) assigned to 2 study groups using a centralized randomization system on 
internet at Visit 1 (Day  1). The randomization algorithm will use a minimization procedure 
accounting for age (60 to 69, 70 to 79 or ≥ 80 years) and center. Minimization f actors will have 
equal weight in the minimization algorithm.  
Overall, participants will be enrolled in 3 age categories with a balance between males and 
females. It is intended to enroll:  
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0   
 
23-June-2023 15 of 112 • Approximately 40% of participants 60 to 69 YOA, approximately 30% of participants 
70 to 79 YOA and approximately 10% of participants ≥ 80 YOA. The remaining 20% can 
be distributed freely across the 3 age categories.  
• Approximately 40% of participants from each sex; the remaining 20% can be distributed freely between the 2 sexes.  
Duration of study : The total duration of the study, per participant, will be approximately 
6 months for the co-ad group, and 7 months for the control group.  
Co-administration (Co -ad) group : Study intervention administration RSVPreF3 OA 
investigational vaccine and PCV20 vaccine on Visit 1 (Day  1) and follow-up for 6 months, 
until end of study (EoS). Two site visits (Visit 1 [Day 1] and Visit 2 [Day 31]) and a phone 
contact 6 months post- last dose.  
Control group : Study intervention administrations of PCV20 vaccine on Visit 1 (D ay 1) and 
RSVPreF3 OA investigational vaccine on Visit 2 (Day 31) and -follow- up for 6  months, until 
EoS. Three site visits (Visit 1 [Day 1], Visit 2 [Day 31], and Visit 3 [Day 61]) and a phone 
contact 6 months post- last dose.  
Number of Participants:  
Approximately 1090 participants aged ≥60 years  will be randomly (1:1) assigned to 2 study 
groups ( i.e., co-ad group or the control group). 
Safety monitoring: the study will be conducted with oversight by the project Safety Review 
Team.  
CONFIDENTIAL  Protocol 219276 (RSV OA=ADJ -019)  
 Amendment v1.0  
  
 
 23-June-2023 16 of 112 1.2 Schema  
Figure  1 Study Design Overview  
   
AE=Adverse Event; Co-Ad group= Co-A dministration group; D=Day; N=Number  of participants; PCV=20 -valent pneumococcal conjugate vaccine; 
pIMD=potential Immune -Mediated Disease; RSV=RSVPreF3 OA; SAE= Serious Adverse Event .  
 

CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023 19 of 112 ● is used to indicate a study procedure that requires documentation in the individual eCRF.  
○ is used to indicate a study procedure that does not require documentation in the individual eCRF.  
∆ is used to indicate a study procedure that requires documentation in the eDiary . 
a Visit 2 should preferably be done on site but if deemed necessary (during special circumstances such as the COVID -19 pandemic), this study visit can be 
replaced by a home v isit conducted by authorized staff. Any information from the participant required according to study procedures and not colle cted during 
the home visit can be obtained by means of a phone call conducted by the site staff.  
b Six months after last vaccinatio n. For this contact, multiple formats ( e.g., email, text message, fax , or phone call) can be proposed by the study site.  
c Visit window shown in  Table 3. 
d Sample collected at Day 1 will be used as baseline for RSV and PCV20 antibody titers.  
e Sample collected at Day 31 will be used for the post -vaccination RSV vaccine- and PCV20 vaccine -related testing.  
f The route for measuring  body  temperature can be oral or axillary. Fever is defined as temperature ≥ 38.0 °C/100.4 °F, regardless of the location of measurement.  
g Designated site staff should review the eDiary frequently during the active event collection period to assess participant/caregiver compliance and monitor 
reported events.  
h SAEs related to study participation, or to a concurrent GSK medication/vaccine sho uld be collected from the time of consent obtained (prior to study vaccine 
administration) up to end of study (EoS) . 
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023 22 of 112 ∆ is used to indicate a study procedure that re quires documentation in the individual e Diary.  
a Visit 3 should preferably be done on site but if deemed necessary (during special circumstances such as the COVID -19 pandemic), this study visit can be 
replaced by a home visit conducted by authorized staff.  Any information from the participant required according to study procedures and not collected during 
the home visit can be obtained by means of a phone call conducted by the site staff.  
b Six months after last vaccination. For this contact, multiple formats ( e.g., email, text message, fax , or phone call) can be proposed by the study site.  
c Visit window shown in Table 4 
d Sample collected at Day 1 will be used as baseline for PCV20 antibody titers.  
e Sample collected at Day 31 will be used for the post -vaccination PCV20 vaccine -related testing. This sample will also be used as baseline for the RSV 
vaccination in the Control group.  
f Sample collected at Day 61 will be used for the post -vaccination RSV vaccine- related testing . 
g The route for measuring body temperature can be oral  or axillary. Fever is defined as temperature ≥ 38.0°C/100.4°F, regardless of the location of measurement.  
h Designated site staff should review the eDiary frequently during the active event collection period to assess participant/caregiver compliance and monitor 
reported events.  
iSAEs related to study participation, or to a concurrent GSK medication/vaccine should be collected from the time of consent obtained (prior to study vaccine 
administration) up to EoS . 
CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023 23 of 112 Table 3 Interval Between Study Visits (Co -ad Group)  
Interval  Planned visit interval  Allowed interval (Visit window) 
Visit 1 (Day 1 /study intervention administration ) → Visit 2 (Day 31)  30 days  30-42 days  
Visit 1 → phone contact  180 days  180-210 days  
 
Table 4 Interval Between Study Visits (Control Group)  
Interval  Planned visit interval  Allowed interval (Visit window) 
Visit 1 (Day 1 /study intervention administration ) → Visit 2 (Day 31)  30 days  30-42 days  
Visit 2 (Day 31 /study intervention administration ) → Visit 3 (Day 61)  30 days  30-42 days  
Visit 2 → phone contact  180 days  180-210 days  
 
 
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  24 of 112 2.0 INTRODUCTION  
2.1 Study Rationale  
GlaxoSmithKline Biologicals SA (GSK) is developing a new respiratory syncytial virus 
(RSV) PreFusion protein 3 Older Adult (OA) investigational vaccine (RSVPreF3 OA) against 
RSV- associated (subtypes A and B) disease in adults ≥60 years of age (YOA). The va ccine 
development is currently in Phase III, and immunogenicity, safety, and reactogenicity of the candidate vaccine when co -administered with other vaccines are being investigated.  
The present study will assess the immunogenicity, safety, and reactogenici ty of the 
RSVPreF3  OA investigational vaccine when co- administered with the 20 -valent 
pneumococcal conjugate vaccine (referred to as Prevnar 20 in USA or Apexxnar in Europe 
[hereafter referred to as PCV20]) in adults ≥60 YOA.  
2.2 Background 
Respiratory syncyti al virus can cause severe lower respiratory tract infection in older adults 
and adults with chronic medical conditions including cardiopulmonary and immunocompromising conditions.  
Based on epidemiological data collected prospectively in 2008-2010 in 14 countries 
worldwide (including North America, Europe, and East Asia), the average percentage of 
documented RSV infection in older adults with influenza- like illness is 7.4%, with values 
between 0% and 17.1% across countries
1. In 2015, an estimated 1.5 million episodes of 
RSV- related acute respiratory illness occurred in older adults in industrialized countries; 
approximately 14.5% of these episodes involved a hospital admission.2 Further information o n 
RSV incidence and disease burden can be found in the Investigator’s Brochure (IB). 
There are 2 subtypes of RSV virus- RSV- A and RSV- B. RSV virus circulates with other 
respiratory v
iruses, and infections peak during winter period. To date, no licensed vaccine or 
prophylactic treatment is available for RSV. Currently available treatment for RSV infection 
is limited to supportive care.  Like RSV, pneumococcal disease also presents high disease 
burden among older adults and the seasonality of RSV disease and invasive pneumococcal 
disease is similar .3,4  
Pneumococcal vaccines f or adults are available in both conjugated and polysaccharide 
formulations. A  PPSV23  is licensed, along with conjugated pneumococcal vaccines including, 
PCV15 and PCV20. Currently the recommendations for pneumococcal vaccination vary from country to countr y. Some countries recommend polysaccharide vaccine, other recommend 
conjugate vaccine, while some recommend the use of both.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  25 of 112 2.3 Benefit/Risk Assessment  
2.3.1 Risk Assessment  
Detailed i nformation about the known and expected benefits and potential risks and 
reasonably expected adverse events (AEs) of the RSVPreF3 OA investigational vaccine can 
be found in the Investigator’s Brochure (IB ) and Development Safety Update Report (DSUR) .  
Study participants must be observed closely for at least 30 minutes after the administration of 
the study interventions. Appropriate medical treatment must be readily available during the observation period in case of anaphylaxis and/or syncope.  
 
Important Po tential/Identified Risk  Mitigation Strategy  
RSV investigational vaccine  
Potential immune -mediated diseases (pIMDs) are 
considered a potential risk, as for all vaccines 
containing an adjuvant system.  Refer to Section 10.3.3 for details.  
Syncope and hypersensitivity reactions (including anaphylaxis).  
 All participants will remain under observation at the clinical  center for at least 30 minutes after 
vaccination.  
Participants with a history of hypersensitivity or severe allergic reaction to any component of the vaccine are excluded from study enrollment.  
Study procedures  
Intramuscular vaccination commonly precipitates a 
transient and self -limiting local inflammatory 
reaction. This may typically include pain at injection site, erythema/redness, and swelling.  As a mitigation strategy, physicians can implement the measures that they consider necessary .
 
Pain a nd bruising may occur at the site where blood 
is drawn.  As a mitigation strategy, physicians can implement the measures that they consider necessary.
 
Syncope (fainting) can occur following or even before any blood draw as a psychogenic response to the needle insertion.  Participants who mention experiencing previous episodes of fainting or dizziness before, during or after a blood draw, will remain under observation at 
the clinical center until deemed necessary by site 
personnel. Appropriate medical treatment must be readily available during this period . 
Abbreviations: PCV20=20 pneumococcal serotypes vaccine; pIMD=potential immune -mediated disease; RSV=respiratory 
syncytial virus. 
For expected adverse reactions associated with Pfizer’s PCV20 vaccine, please refer to the 
Prescribing Information. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  26 of 112 2.3.2 Benefit Assessment  
The participant s may have the benefit of being protected against RSV infection  during the 
active season.  In a large Phase III vaccine clinical trial in adults aged 60 years and above,  the 
RSVPreF3 investigational vaccine candidate demonstrated overall vaccine efficacy of 82.6% 
(96.95% confidence interval [CI], 57.9 to 94.1) against RSV lower respiratory tract disease (RSV- LRTD) .
5 The vaccine was well tolerated with a favorable safety profile.  
All participants  in this study will also receive PCV20 vaccine as part of this study, which is 
one of the most recently developed pneumococcal vaccines and is recommended in US for adults ≥65 years of age for the prevention of pneumococcal disease.  
An indirect benefit is that the information obtained in this study will generate more knowledge about the RSV vaccine and the possibility to be co-administered with pneumococcal vaccine. Another be nefit for all study participants may include gaining  information about their general 
health status through the recurrent medical evaluations/assessments associated with this study 
(i.e., physical examination). 
2.3.3 Overall Benefit -Risk Conclusion 
The RSVPreF3 OA investigational vaccine is in clinical development. Considering the recent 
data on the vaccine efficacy, and measures taken to minimize the risk to participants in this 
study the potential risks are justified by the potential benefits linke d to the development of this 
vaccine.  
Prevnar 20™  is a vaccine indicated for active immunization for the prevention of pneumonia 
and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  27 of 112 3.0 OBJECTIVES, ENDPOINTS, AND ESTIMANDS  
 
Objectives  Endpoints and Estimands  
Primary * 
• To demonstrate the non -inferiority of 
PCV20 when co -administered with the  
RSVPreF3 OA investigational vaccine 
compared to PCV20 administered alone  • Opsonophagocytic (OP) antibody (Ab) titers 
for each of the pneumococcal vaccine serotype 
(ST) expressed as between groups geometric 
mean titer (GMT) ratio, 1 month after the PCV20  dose 
• To demonstrate the non -inferiority of 
RSVPreF3 OA  investigational vaccine  in 
terms of RSV -A neutralization antibodies 
when co -administered with PCV20 
compared to RSVPreF3 OA investigational vaccine administered alone  • RSV -A neutralizing Ab titers expressed as 
between groups GMT ratio, 1 month after the RSVPreF3 OA investigational vaccine dose   
• To demonstrate the non -inferiority of 
RSVPreF3 OA investigational vaccine in 
terms of RSV -B neutralization antibodies 
when co -administered with the PCV20 
vaccine compared to RSVPreF3 OA 
investigational vaccine administered alone  • RSV -B neutralizing Ab titers expressed as 
between groups GMT ratio, 1 month after the RSVPreF3 OA investigational vaccine dose  
Secondary  
• To evaluate the humoral immune response to RSVPreF3 OA investigational vaccine 
when co -administered with the PCV20 or 
administered alone  • RSV -A neutralizing Ab titers expressed as 
mean geometric increase (MGI) over baseline 
at 1 month after the RSVPreF3 OA 
investigational vaccine dose  
• RSV -B neutralizing Ab titers expressed as MGI 
over baseline at 1 month after the RSVPreF3 OA investigational vaccine dose  
• To evaluate the safety and reactogenicity following administration of the RSVPreF3 
OA investigational vaccine and PCV20, 
co-administered or administered alone.  • Percentage of participants reporting each solicited event with onset within 7 days after 
vaccine administration ( i.e., the day of 
vaccination and 6 subsequent days)  
• Percentage of participants reporting unsolicited AE within 30  days after vaccine administration 
(i.e., the day of vaccination and 29 subsequent 
days) 
• Percentage of participants reporting SAEs after vaccine administration (Day 1) up to EoS 
(6 months after last vaccination)  
• Percentage of participants reporting pIMDs after vaccine administration (Day 1) up to EoS 
(6 months after last vaccination)  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  28 of 112 Footnote s for the Objectives, Endpoints, and Estimands table.  
Abbreviations: Ab=antibody; AE=adverse event; EoS=end of study; GMT=geometric mean titer; MGI=mean 
geometric increase; OA=older adult; OP=opsonophagocytic; PCV 20=20-valent pneumococcal vaccine; 
pIMD=potential  immune -mediated disease; RSV=respiratory syncytial virus; RSVPreF3 OA=respiratory 
syncytial virus PreFusion protein 3 older adult investigational vaccine; SAE=serious adverse event; 
ST=serotype.  
* PCV and RSV-A endpoint will be assessed as co -primary and following the current success RSV -B will be 
demonstrated a s sequential. Refer to Section 9.3.1.1  for the testing sequence of primary objectives.  
 
Details related to attributes of estimand covering intercurrent events, population and treatment 
definition are provided in the Section 9.0. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  29 of 112 4.0 STUDY DESIGN 
4.1 Overall  Design  
The Study Design Overview is provided in Figure 1. 
Experimental design : Phase III, open-label, randomized, controlled, multi-country study with 
2 parallel groups.  
Study groups and Randomization: Approximately 1090 eligible participants will be 
randomly (1:1) assigned to 2 study groups using a centralized randomization system on 
internet at Visit 1 (Day  1). The randomization algorithm will use a minimization proce dure 
accounting for age (60 to 69, 70 to 79 or ≥ 80 years) and center. Minimization factors will have 
equal weight in the minimization algorithm.  
Overall, participants will be enrolled in 3 age categories with a balance between males and females. It is inte nded to enroll: 
• Approximately 40% of participants 60 to 69 YOA, approximately 30% of participants 70 to 79 YOA, and approximately 10% of participants ≥80 YOA. The remaining 20% can be distributed freely across the 3  age categories.  
• Approximately 40% of participants from each sex; the remaining 20% can be distributed freely between the 2 sexes.  
Duration of study : The total duration of the study, per participant, will be approximately 
6 months for the co-ad group, and 7 months for the control.  
Safety monitoring:  the study will be conducted with oversight by the project Safety Review 
Team (SRT). See Section 10.1.6 fo r SRT structure.  
Co-administration (Co -ad) group : Study intervention administration RSVPreF3 OA 
investigational vaccine and PCV20 vaccine on Visit 1 (Day 1 ) and follow-up for 6 months, 
until end of study (EoS). Two site visits ( Visit 1 [Day 1] and Visit 2 [D ay 31]) and a phone 
contact 6 months post- last dose.  
Control group : Study intervention administrations of PCV20  vaccine on Visit 1 (D ay 1) and 
RSVPreF3 OA investigational vaccine on Visit 2 (Day 31) and follow-up for 6 months, until 
EoS. Three site visits ( Visit 1 [Day 1], Visit 2 [Day 31] and Visit 3 [D ay 61]) and a phone 
contact 6 months post- last dose.  
See Table 5  for study interventions administered.  
 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  30 of 112 4.1.1 Overview of the Recruitment Plan  
No separate screening visit is planned for this study. The study is planned to be conducted at 
sites in multiple countries. The recruitment plan will be defined by each participating site.  
The recruitment plan may be adapted based on the actual number of participants enrolled in 
each country. In case a site would fall behind in participant recruitment, a redistribution of the enroll ment target per site in the participating countries may be made. This would allow the 
other participating sites to enroll additional participants to ensure full and timely enroll ment of 
the overall targeted number of participants specified in this protocol. 
The procedures for participants identification/recruitment must be approved by the 
Independent Ethics Committee (IEC)/Institutional Review Board (IRB) together with the 
material intended for participants identification/recruitment and particip ants use.  
4.1.2 Enro llment Rules  
Overall, participants will be enrolled in 3 age categories reflecting an approximate age 
distribution in the general population with a balance between males and females. It is 
therefore intended to enroll: 
• Approximately 40% of participants 60  to 69 YOA, approximately 30% of participants 
70 to 79 YOA, and approximately 10% of participants ≥80 YOA. The remaining 20% can 
be distributed freely across the 3 age categories.  
• Approximately 40% of participants from each sex; the remaining  20% can be distributed 
freely between the 2 sexes.  
4.2 Scientific Rationale for Study Design 
GlaxoSmithKline Biologicals SA (GSK) is developing a new respiratory syncytial virus (RSV) PreFusion protein 3 Older Adult (OA) investigational vaccine (RSVPreF3 OA) against 
RSV- associated (subtypes A and B) disease in adults ≥ 60 years of age (YOA). The vaccine 
development is currently in Phase III, and immunogenicity, safety, and reactogenicity of the 
candidate vaccine when co -administered with other vaccines are being investigated.  
Like RSV, pneumococcal disease also presents high disease burden among older adults. Moreover, the seasonality of RSV disease and invasive pneumococcal disease is similar.  
The present study will assess the immunogenicity, safety, and reactogenicity of the RSVPreF3 
OA investigational vaccine when co-administered with the pneumococcal conjugate vaccine 
(referred to as Prevnar 20 in USA or Apexxnar  in Europe  [hereafter referred  to as PCV20]) in 
adults ≥60 YOA.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  31 of 112 4.3 Justification for Dose   
Based on the results up to 1-month post-Dose 2 from study RSV OA=ADJ -002, a single dose 
regimen (0.5 mL) and the 120 µg RSVPreF3/AS01 E formulation were selected for further 
evaluation in the Phase 3 clinical program. The RSV OA=ADJ-002 study was designed to 
assess the immunogenicity of a 2 -dose AS01-adjuvanted or unadjuvanted vaccine 
administered according to a 0 -, 2-month schedule with the aim to maximize the immune 
response against RSV and vaccine efficacy over several seasons. Based on the data from clinical development programs for AS01 -adjuvanted protein antigen vaccines in OA, such as 
Shingrix and the chronic obstructive pulmonary disease (COPD) investigational vaccine, it 
was expected th at immunological responses would reach higher levels 1  month post- Dose 2 as 
compared with 1- month post -Dose 1. However, the RSV OA=ADJ -002 results demonstrated 
that the second dose given 2 months after the first dose had no added value in terms of humoral and/or cellular immune responses. The humoral response, both in terms of RSV- A 
neutralizing antibody GMTs and RSVPreF3 IgG geometric mean concentrations (GMCs), peaked 1 month after the first dose, and the second dose did not increase the level observed after first dose.  
The results from study RSV OA=ADJ -002 demonstrated statistically significant superiority of 
the 120 µg formulations in terms of RSV -A neutralizing titers over at least one of the 30 µg 
and 60 µg formulations with the same adjuvant content or unadjuvanted. The data 
demonstrated an immunologic benefit of any AS01
E or AS01 B formulations over 
unadjuvanted formulations in terms of frequency of RSVPreF3 -specific CD4+ T cells 
expressing at least 2 markers. Importantly, despite lower baseline observed in OA, the AS01 -containing formulations induced CD4+ T cells frequencies at a close or similar level as 
in young adults, that is not observed with the unadjuvanted formulations. 
There was no safety concern detected in unadjuvanted groups to be linked to the RSVPreF3 
antigen assessed for the first time in OA. The acceptable safety/reactogenicity profile in all 
120 µg groups, together with the immunological benefit demonstrated for the 120 µg antigen dose, supports the selection of a 120 µg based formulation. The results also showed that all the 
AS01 -adjuvanted formulations evaluated are considered to have a clinically acceptable safety 
profile. The AS01- adjuvanted formulation with the lowest reactogenicity profile, i.e., the 
AS01
E-based f ormulation, was selected. The immunological response observed after 1 vaccine 
dose of the AS01 E-based formulation is considered adequate for a RSVPreF3 OA candidate 
vaccine.  
In the current study, the PCV20 vaccine will be administered as a 0.5 mL single-dose 
pre-filled syringe as per  Prescrib ing Information. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  32 of 112 4.4 End of Study Definition  
A participant is considered to have completed the study if he/she returns for the last visit  as 
described in the protocol. 
End of Study is the last subject  last visit (LSLV)  (contact at 6 months post -last dose) . 
4.5 Study Stopping Criteria 
Not applicable for this study.  
4.6 Participant Input into Design 
Not applicable for this study. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  33 of 112 5.0 STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment cri teria, also known 
as protocol waivers or exemptions, is not permitted. 
5.1 Inclusion Criteria  
All participants must satisfy all  the following criteria at study entry:  
• A male or female ≥60 YOA at the time of the first study intervention administration.  
• Participants who, in the opinion of the investigator, can and will comply with the 
requirements of the protocol (e.g., completion of the e Diary, return for follow -up 
visits, ability to access and utilize a phone or other electronic communic ations).  
o Note: In case of physical incapacity that would preclude the self-completion of the e Diary, either site staff can assist the participant (for activities performed 
during site visits) or the participant may assign a caregiver* to assist him/her with this activity (for activities performed at home). However, at no time will 
the site staff or caregiver* evaluate the participant’s health status while 
answering diaries or make decisions on behalf of the participant. 
*A ‘caregiver’ is a person who has a continuous caring role for a participant or may be a 
person having substantial periods of contact with a participant and/or is engaged in his/her 
daily health care ( e.g., a relative of the participant including family members or friends).  
• Written or witnes sed informed consent  obtained from the participant prior to any 
study-specific procedure being performed. 
• Participants living in the general community or in an assisted -living facility that 
provides minimal assistance, such that the participant is primarily responsible for 
self-care and activities of daily living.  
• Participants who are medically stable in the opinion of the investigator at the time of first study intervention administration. Participants with chronic stable medical conditions with or  without specific treatment, such as diabetes mellitus, hypertension , 
or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.  
 
5.2 Exclusion Criteria   
The following criteria should be checked at the time of study entry. The potential participant MAY NOT be included in the study if ANY exclusion criterion applies:  
5.2.1 Medical Conditions  
• Any confirmed or suspected immunosuppressive or immunodeficient condition 
resulting from disease ( e.g., current malignancy, human immunodeficiency virus) or 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  34 of 112 immunosuppressive/cytotoxic therapy ( e.g., medication used during cancer 
chemotherapy, organ transplantation, or to treat autoimmune disorders), based on 
medical history and physical examination (no laboratory testing required). 
• History of any reaction or hypersensitivity (e.g., anaphylaxis) likely to be exacerbated 
by the study interventions, in particular any history of severe allergic reaction to any vaccine containing diphtheria toxoid (for example, diphtheria-tetanus- pertussis 
[DTaP ]), or PPSV23.  
• Participants considered by investigator as suffering from s erious or unstable chronic 
illness.  
• Any history of dementia or any medical condition that moderately or severely impairs 
cognition. 
o Note: If deemed necessary for clinical evaluation, the investigator can use tools such as Mini- Mental State Examination (MMSE), Mini-Cog or Montreal 
Cognitive Assessment (MoCA) to determine cognition levels of the participant. 
• Recurrent or uncontrolled neurological disorders or seizures. Participants with medically  -controlled chronic neurological diseases can be enrolled in the study as per 
investigator assessment, provided that their condition will allow them to comply with 
the requirements of the protocol (e.g., completion of the eDiary, attend regular phone 
calls/study site visits).  
• Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life -threatening disease likely to limit survival 
up to EoS).  
• Any medical condition that in the judgment of the investigator would make 
intramuscular injection unsafe.  
5.2.2 Prior and Concomitant Therapy  
• History of previous vaccination with any licensed or investigational pneumococcal conjugate vaccine, or planned receipt through study participation.  
• History of previous vaccination with any licensed or investigational pneumococcal polysaccharide vaccine in the last 5 years from enrol lment, or planned receipt through 
study participation. 
• Previous vaccination with any licensed or investigational RSV vaccine  
• Use of any investigational or non- registered product (drug, vaccine or medical device) 
other than the study interventions during the period beginning 30 days before the first dose 
of study interventions and ending 30 days after the last study intervention administration, 
or their planned use during the study period. 
• Planned or actual administration of a vaccine not foreseen by the study protocol in the 
period starting 30 days before the first study intervention administration and ending 
30 days after the last study intervention administration.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  35 of 112 o Planned or actual administration of adjuvanted quadrivalent influenza vaccine or 
live influenza vaccine not foreseen by the study protocol in the period starting 
30 days before the first study intervention administration and ending 30 days after 
the last study intervention administration.  
Note: In case an emergency mass vaccination for an unforeseen public health 
threat ( e.g., a pandemic) is recommended and/or organized by the public health 
authorities outside the routine immunization program, the time period described 
above can be reduced if necessary for that vaccine, provided it is used according 
to the local governmental recommendations and that the Sponsor or designee is 
notified accordingly. 
• Administration of long- acting immune -modifying drugs during the period starting 
180 days before the administration of first dose of study interventions or planned administ ration at any time during the study period (e.g., infliximab). 
• Administration of immunoglobulins and/or any blood products or plasma derivatives 
during the period starting 90 days before the administration of first dose of study 
interventions or planned administration during the study period. 
• Chronic administration (defined as more than 14 consecutive days in total) of 
immunosuppressants or other immune -modifying drugs during the period starting 90 days 
prior to the first study intervention dose or planned administration during the study period. 
For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and 
topical steroids are allowed.  
5.2.3 Prior/Concurrent Clinical Study Experience  
• Concurrently participating in another clinical study, at any time during the study period, in 
which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or invasive medical device). 
Note: European Economic Community (EEC) directive 93/42/EEC defines an invasive 
medical device as ‘A device which, in whole or in part, penetrates inside the body, either through a body orifice or through the surface of the body.’ 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  36 of 112 5.2.4 Other Exclusions 
• History of chronic alcohol consumption and/or drug abuse as deemed by the investigator 
to render the potential participant unable/unlikely to provide accurate safety reports or 
comply with study procedures. 
• Bedridden participants.  
• Planned move during the study conduct that prohibits participation until study end. 
• Participation of any study personnel or their immediate dependents, family, or household 
members.  
5.3 Caregiver Support  
Study participants may decide to assign a caregiver to help them fulfill the study procedures. Please refer to the Glossary of Terms  for the definition of a caregiver.  
A caregiver can be appointed by the participant at any time during the study, when the participant feels it is necessary. Each careg iver should receive the caregiver information letter 
before providing support to the study participant. Ideally, a single caregiver should be appointed by the participant but, in some situations, it may happen that several caregivers will support a study participant throughout the conduct of the study. This should be recorded in the 
source documents.  However , every effort should be made to ensure that only one caregiver 
enters the data into the eDiary  to allow for timely completion.  
Caregivers may help the study participants with performing some practical study procedures such as receiving or making phone calls to site staff, planning study visits, transcribing 
responses to diaries, transportation to and from the study site etc. However, at no time, the caregiver should evaluate the participant’s health status while answering diaries or make 
decisions on behalf of the participant. At the first study visit (Visit 1  [Day 1] ) the site staff 
should inform the participant of the possibility to appoint a caregiver. Then at subsequent 
study visit(s), the site staff should check again with the participant if he/she wishes to appoint a caregiver or if there were or will be changes of caregiver.  
 
5.4 Lifestyle Considerations  
Not applicable for this study. 
5.5 Screen Failures  
A screen failure occurs when a participant who has consented to participate in the clinical study is not subsequently randomized to study intervention/entered in the study. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  37 of 112 Limited data for screening failures (including reason for screening failur e and any SAEs 
related to study participation, or to a concurrent GSK medication/vaccine from the time of 
consent obtained) will be collected and reported in the eCRF. 
Individuals who do not meet the criteria for participation in this study (screen failure ) but at 
some point, in the future are expected to meet the eligibility criteria may be rescreened. 
Individuals who are rescreened will be assigned a new participant number and will undergo 
the informed consent process, and then restart a new screening pha se. 
5.6 Criteria for Temporarily Delaying  
Study intervention administration may be postponed within the permitted time interval as 
deemed appropriate by the investigator until transient conditions cited below are resolved  and 
prior to the EoS enrollment period:  
• Acute disease and/or fever at the time of study intervention administration. Refer to Section 1.3 ( Schedule of Activities [ SoA]) for definition of fever and location for 
measuring body temperature in this study.  
• Participants with a minor illness (such as mild diarrhea) without fever may be dosed at the discretion of the investigator.  
• Participants with symptoms suggestive of active Coronavirus Disease 2019 (COVID-19) 
infection (e.g., fever, cough, etc.). The return of the participant to the site will follow the 
specific guidance from local public health and other competent authorities ( e.g., free of 
symptoms, COVID -19 negative testing, etc.).  
• Participants with known contact with COVID- 19 positive individual may be vaccinated at 
least 14  days after the exposure, provided that the participant remains symptom -free, and 
at the discretion of the investigator.  
• In case of administration of inactivated and subunit influenza vaccines or COVID-19 vaccines (fully licensed or with EUA): postponement of study intervention administration 
within given protocol timelines and prior to the end of the study enrollment period, to allow respect of at least 14 days interval between flu/COVID -19 vaccination and study 
intervention administration. 
• Use of antipyre tics and/or analgesics and/or antibiotics within 3 days prior to study 
intervention administration. 
• Other issues ( e.g., technical, or administrative) preventing dose administration on day of 
visit. 
• In case of delayed enrollment, all visit activities will b e repeated  when the participant is 
able to return for the visit. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  38 of 112 For Visit 1, if the planned study intervention administration is  delayed , blood sampling does 
not need to be repeated if it was obtained during enrollment visit. The following procedures 
must be repeated prior to the delayed study intervention administration : 
• Body temperature  
• Re-check contraindications, warnings, precautions to study intervention 
• Re-check inclusion/exclusion criteria   
Visit window for Visit 2 starts from day of first study intervention administration. 
For delay in the study intervention administration during Visit 2 of the control group, the 
following procedures must be repeated : 
• Body temperature  
• Re-check contraindications, warnings, precautions to study intervention 
• Re-check inclusion/exclusion criteria 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  39 of 112 6.0 STUDY INTERVENTION(S) AND CONCOMITANT 
THERAPY 
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to a study participant according to 
the study protocol. Refer to the  Glossary of Terms  for the definition of study intervention.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  40 of 112 6.1 Study Interventions Administered  
Table 5 Study Interventions Administered  
Study Intervention  Name:  RSVPreF3 OA 
Investigational  Vaccine  Prevnar 20/Apexxnar  
Study intervention formulation  
RSVPreF3 
(120 µg) AS01 E: QS-
21* (25  µg), 
MPL  (25µg), 
liposomes; 
Water for 
injection  PS1(2.2 µg)¹ ʼ²; PS3(2.2 µg)¹ʼ²; 
PS4(2.2 µg)¹ʼ²; PS5(2.2 µg)¹ʼ²; 
PS6A(2.2 µg)¹ʼ²; PS6B(4.4 µ g)¹ʼ²; 
PS7F(2.2 µg)¹ʼ²; PS8(2.2 µ g)¹ʼ²; 
PS9V(2.2 µg)¹ʼ²; PS10A(2.2 µ g)¹ʼ²; 
PS11A(2.2 µg)¹ʼ²; PS12F(2.2 µg)¹ʼ²; 
PS14(2.2 µg)¹ʼ²; PS15B(2.2 µg)¹ʼ²; 
PS18C(2.2 µg)¹ʼ²; PS19A(2.2 µg)¹ ʼ²; 
PS19F(2.2 µg)¹ʼ²; PS22F(2.2 µg)¹ʼ²; 
PS23F(2.2 µg)¹ʼ²; PS33F(2.2 µg)¹ʼ²; 
¹conjugated to CRM₁₉₇ (51 µg); 
²adsorbed on AlPO₄ (0.125 mg 
Al³⁺); Water for injections  
Presentation  Vial; 
powder 
for 
suspension 
for 
injection  Vial; 
suspension 
for 
suspension 
for injection  Suspension for injection  
Route of Administration  Intramuscular use  Intramuscular use  
Product category  Biologic  Biologic  
Type  Study Study 
Administration site   
Location  Deltoid  Deltoid  
Laterality  Non-dominant  Co-ad group: Dominant  
Control group: Non -dominant 
Number of doses to be  
administered  1 1 
Dose Volume**  0.5 mL  0.5 mL  
Packaging, labeling *** Refer to Pharmacy Manual 
for details  Refer to Pharmacy Manual for 
details  
Manufacturer  GSK  Pfizer  
Abbreviations: Al=aluminum; AlPO 4=aluminum phosphate; AS01 E=Adjuvant System 01; CRM=cross -reactive 
material; PS=pneumococcal serotype; QS-21=Quillaja saponaria Molina, fraction 21; MPL =monophosphoryl 
lipid A.  
*Licensed by GSK from Antigenics Inc, a wholly owned subsidiary of Agenus Inc., a Delaware, USA 
corporation.  
**Refer to the Pharmacy Manual for the volume after reconstitution.  
***Labeling is compliant with the requirements of applicable regulatory agencies.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  41 of 112 6.1.1 Medical Devices  
There are no GSK manufactured medical devices (or devices manufactured for GSK by a third 
party) provided for use in this study. Other medical devices (not manufactured by or for GSK) 
provided for use in this study are: thermometer, syringe, needle, and pre -filled syringe for 
PCV20. All medical devices are CE marked and will be used for their intended use. Instructions for medical device use are provided in the package insert.  
All device deficiencies (including malfunction, use error and inadequate labeling) shall be documented and reported by the investigator throughout the clinical investigation (see Sections 8.3.6 a nd 10.3) and appropriately managed by GSK.  
6.2 Preparation, Handling, Storage , and Accountability  
The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received , and any discrepancies are 
reported and resolved before use of the study intervention. 
Only participants enrolled in the study may receive study intervention, and only authorized 
study site staff may supply or administer study intervention.  
All study interventions must be stored in a secure, environmentally controlled, and monitored 
(manual or a utomated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized study site staff.  The storage temperature should be 
continuously monitored and recorded with a calibrated (if not validated) temperature 
monitoring device(s).  
The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance ( i.e., 
receipt, reconciliation, and final disposition records).  
The investigator, a member of the study site  staff, or a hospital pharmacist must maintain an 
adequate record of the receipt and distribution of all study intervention s using the Drug 
Accountability Form. These forms must be available for inspection at any time.  
Further guidance and information for the final disposition of unused study interventions are provided in the Pharmacy Manual. 
6.3 Measures to Minimize Bias: Randomization and Blinding  
6.3.1 Participation Identification  
Participant identification numbers (IDs) will be assigned sequentially to the participants who have consented to participate in the study, according to the range of participant IDs allocated 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  42 of 112 to each study center. The participant IDs will be documented in the electronic Case Report 
Form (eCRF).  
The eligibility of the participant will be determined based on the inclusion and exclusion criteria listed in Section 5.0. T he participant ID will be the participant’s unique identification 
number for all eCRFs and associated study documentation that will be used for duration of the 
study. If the participant is terminated from the study, their participant ID cannot be 
re-assigned. 
6.3.2 Randomization to Study Intervention 
All eligible participants will be centrally randomized to the study group at a 1:1 ratio using 
Interactive Web Response System (IWRS) randomization (refer to  Glossary of Terms  for a 
definition of IWRS).  
The participants will receive a unique intervention number ( refer to  Glossary of Terms  for a 
definition of a treatment number) . Once a treatment  number has been assigned, it cannot be 
re-assigned. 
6.3.3 Intervention Allocation to the Participant 
Approximately 1090 eligible participants will be randomly (1:1) assigned to 2 study groups 
using a centralized randomization system on internet at Visit 1 (Day  1). The randomization 
algorithm will use a minimization procedure accounting for age (60 to 69, 70 to 79 or 
≥80 years) and center. Minimization factors will have equal weight in the minimization 
algorithm.  
After obtaining the signed and dated Informed Consent Form ( ICF) from the participant and if 
the participant eligible , the delegated clinical trial staff will access I WRS. Upon entering the 
participant ID and age, the randomization system will determine the treatment  group and 
provide the treatment  number to be used for the trial intervention. The treatment number(s) to 
be used for subsequent dose administration(s) will be provided by the same IW RS. 
Instructions related to instances when I WRS is not available will be provide to the site . 
Refer to the IWRS user manual  for additional information related to the treatment  number 
allocation.  
6.3.4 Allocation of P articipants to Assay Subsets 
Immunogenicity assessments are planned as outlined in  Section 8.1.  
Refer to Section 9.2 fo r descriptions of analysis populations.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  43 of 112 6.3.5 Blinding and Unblinding  
This is an open -label study. The participant and principal investigator will not be blind to the 
intervention administered.   
The laboratory in charge of sample testing will be blinded to the study intervention 
assignment. Codes will be used to link the participant and study to each s ample. There will be 
no link between the study intervention and the identity of the participant.  
6.4 Study Intervention Compliance 
When participants are dosed at the site, they will receive study intervention directly from the investigator or designee, under m edical supervision. The mode of administration (i.e., 
intramuscularly), laterality , as well as the date and time of each dose administered in the clinic 
will be recorded in the source documents.  See Section 6.1 for details in intervention 
administration.  
6.5 Dose Modification  
Not applicable. 
6.6 Treatment of Overdose  
Any dose of any study vaccine greater than the one required per protocol is considered an overdose. All cases of vaccine overdose should be reported as protocol deviations. Any signs or symptoms resulting from an overdose should be reported as AEs, or SAEs if SAE criteria 
are met; overdose per se should not be reported as an AE/SAE. GSK does not recommend 
specific treatment for an overdose; however, any resulting adverse reaction should be treated symptomatically. 
6.7 Concomitant Therapy  
At each study visit/contact, the investigator or his/her delegate should question the participant and/or the participant’s caregiver about all medications/products taken, and vaccinations 
received by the participant. 
The following concomitant medication(s)/product(s)/vaccine(s) must be recorded in the eCRF: 
• All concomitant medication s including vaccines , except vitamins and dietary supplements, 
administered after the first dose of study intervention (Day 1 to EoS).  
• All concomitant medication s leading to discontinuation of the study intervention or 
elimination from the analysis, including products/vaccine s (Refer to Section 5.2.2 a nd 
Section 9.2.1). 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  44 of 112 • All concomitant medication which may explain/cause/be used to t reat an SAE  including 
vaccines/products, as defined in Sections 8.3.1 and 10.3.6. These must also be recorded in 
the Expedited Adverse Event report. 
• Any prophylactic medication (eg, analgesics, antipyretics) administered  on the day of 
study vaccination in the absence of any symptom and in anticipation of a reaction  to the 
vaccination. 
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  45 of 112 7.0 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
Discontinuation of specific study sites or of the study as a whole are detailed in 
Section  10.1.10. 
7.1 Discontinuation of Study Intervention  
Discontinuation of study intervention refers to any participant who has not received all 
planned doses of study intervention. A participant who discontinued study intervention may 
continue other study procedures (e.g., safety or immunogenicity), planned in the study 
protocol at the discretion of the investigator.  
The primary reason for premature discontinuation of the study intervention will be 
documented on the eCRF as follows: 
• Adverse event requiring expedited reporting to IQVIA  
• Unsolicited non- serious adverse event   
• Solicited adverse event  
• Not willing to be vaccinated  
• Other (specify)  
If a participant who does not meet enrollment criteria is inadvertently enrolled, that participant 
must be discontinued from study intervention and IQVIA must be contacted. An exception may be granted in rare circumstances for which there is a compelling safety reason to allow 
the participant to continue. In these rare cases, the investigator must obtain documented 
approval from GSK, or designee, to allow the participant to continue in the study. 
Participants who discontinue study intervention will not be r eplaced.  
7.1.1 Contraindications to Subsequent Study I ntervention Administration  
The eligibility for subsequent study intervention administration in the control group must be confirmed before administering any additional dose.  
Participants who meet any of the c riteria listed below or criteria listed in  sections 5.2.1 and 
5.2.2 s hould not receive additional doses of study intervention. Such participants should be 
encouraged to continue other study procedures, at the investigator’s discretion ( 10.3).  All 
relevant criteria for discontinuation of study intervention administration must be recorded in 
the eCRF.  
• Participants who experience any  SAE judged to be possibly or probably related to the first 
study intervention (PCV20 vaccine) and that, in the opinion of the investigator, may pose 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  46 of 112 additional risk to the participant if he/she receives the second study intervention (RSV 
investigational vaccine).  
• Participants who develop any new condition which, in the opinion of the investigator, may pose additional risk to the participant if he/she continues to participate in the study. 
• Anaphylaxis following the administration of study intervention(s) f rom Visit 1 onwards.  
• Any condition that in the judgment of the investigator would make intramuscular injection unsafe.  
7.2 Participant Discontinuation/Withdrawal from the Study  
A participant may withdraw from the study at any time at his/her own request or may  be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, or compliance, or administrative reasons. This is expected to be uncommon. 
A participant is considered to have withdrawn from the study if no new study procedure has 
been performed or no new information has been collected for him/her since the date of 
withdrawal/last contact.  
From an analysis perspective, a study ‘withdrawal’ refers to any participant who did not return for the concluding visit/was not available for the concluding contact planned in the protocol.  
Investigators /site designee will attempt to contact participants who do not return for scheduled 
visits or follow -up. 
All data and samples collected up to and including the date of withdrawal of/last contact wit h 
the participant will be included in the study analyses. 
The primary reason for study withdrawal will be documented in the eCRF, based on the list 
below: 
• Adverse events requiring expedited reporting to IQVIA ( see Appendix 3 for details 
regarding such events) 
• Unsolicited non- serious AEs 
• Solicited event  
• Withdrawal by participant, not due to an AE * 
• Migrated/Moved from the study area 
• Lost to follow -up 
• Sponsor study termination 
• Other (specify) 
*If a participant is withdrawn from the study because he/she/the participant’s caregiver(s)
 has 
withdrawn consent and the reason for withdrawal was provided, the investigator must 
document this reason in the  eCRF.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  47 of 112 Participants who are withdrawn from the study because of AEs/SAEs must be clearly 
distinguished from participants who are withdrawn for other reasons. Investigator will follow 
participants who are withdrawn from the study due to an AE/SAE until the event is resolved 
(see Appendix 3 fo r details regarding follow -up AEs ). 
7.3 Lost to Follow -up 
A participant will be considered ‘lost to follow -up’ if he/she fails to return for scheduled visits 
and cannot be contacted by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: • The study site must attempt to contact the participant and reschedule the missed visit as 
soon as possible, counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether the participant wishes to and/or should continue in the 
study. 
• Before a participant is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact with the participant (where possible, 3 telephone calls, and if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the participant’s 
medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.  
• Study s ite personnel, or an independent third party, will attempt to collect the vital status 
of the participant within legal and ethical boundaries for all participants randomized, including those who did not get study intervention. Public sources may be searched for vital status information. If vital status is determined as deceased, this will be documented , 
and the participant will not be considered lost to follow-up. Sponsor personnel will not be involved in any attempts to collect vital status information.  
• If the participant indicates he/she does not want to continue with the study, he/she will be 
contacted for a final assessment for safety reasons; he/she will be withdrawn from the 
study with reason of “withdrawal of consent. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  48 of 112 8.0 STUDY ASSESSMENTS AND PROCEDURES  
Protocol waivers or exemptions are only permitted when necessary for the management of 
immediate safety concerns for the participant.  
Immediate safety concerns should be discussed with IQVIA as soon as they occur or when the study team becomes aware of them. The purpose of this communication is to determine if the 
participant(s) should discontinue the study intervention. 
Study procedures and their timing are summarized in the SoA (Section 1.3 ).  
Adherence to the study design requirements, including those specified in Section 1.3, is 
essential and required for study conduct. 
All screening evaluations must be completed, and the results reviewed before confirming that 
potential participants meet all eligibility criteria. Participants who have signed informed 
consent but are not eligible to proceed should be recorded in the eCRF with a status of ‘screen 
failure’ (Section 5.5). 
If local regulations allow and quality of study procedure s is maintained, participants can be 
offered remote visits (e.g., telemedicine, home visits)  for the collection of biological samples 
and/or safety data/safety assessment(s). These remote visits must be performed by qualified 
study staff/healthcare professionals (HCPs).  
  
Following procedures can be performed remotely/virtually (refer to the  Glossary of Terms  for 
the definitions of telemedicine, remote and virtual visits): 
• Safety follow -up may be performed by telemedicine which will use secure video 
conferences, phone calls, and a web portal and/or mobile application (or eDiary) as a way of communicating with the participant and monitoring the participant’s progress. In addition, qualified study staff/HCPs may also identify AEs and report them to the 
investigator for evaluation.  
• Biological samples may be collected remotely by qualified study staff/HCPs.  Biological 
samples should be collected only if they can be processed in a timely manner and appropriately stored until the intended use. Remote collection of cell -mediated immunity 
(CMI ) samples is not allowed except for in special circumstances and with the app roval of 
the GSK Central study team.  
• In exceptional situations ( e.g., pandemic), the following approach may be considered: 
o If despite best efforts it is not possible to administer the dose of study intervention 
as defined in the protocol, additional 30 days may be added to the Visit 2 interval (only for RSV investigational vaccine administration in the Control group).  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  49 of 112 Impact on the per protocol set (PPS)  for immunogenicity will be determined on a case-by- case 
basis.  
For information on the role of a caregiver in study assessments and procedures, please refer to 
Section 5.3.  
Procedures conducted as part of routine clinical management (e.g., hematologic profiles), and 
obtained before the participant/participant’s caregiver  signed the ICF, may be used for 
screening and/or for establishing a clinical baseline (provided the procedure met protocol 
specified criteria and was performed within the time frame defined in the SoA [Section 1.3]).  
8.1 Immunogenicity Assessments  
Biological samples will be used for research planned in the protocol and for purposes related to the improvement, development and quality assurance of the labo ratory tests described in 
this protocol.  
Findings in this or future studies may make it desirable to use samples acquired in this study 
for research not planned in this protocol. In this case, all participants in countries where this is allowed will be asked to give consent to allow GSK or a contracted partner, to use the samples 
for further research. The further research will be subject to prior IEC/IRB approval, if required 
by local legislation.  
More specifically, part of the blood sample collected from the participants in this  study may 
be used to perform qualification, validation and/or assay maintenance of future streptococcus pneumonia humoral assays . 
Information on further research and its rationale can be obtained from GSK.  
Sample te sting will be done in accordance with the recorded consent of the individual 
participant/participant’s caregive r.  
By default, collected samples will be stored for a maximum of 20 years. This storage period 
begins when the last participant performs the las t study visit. This timeline can be adapted 
based on local laws, regulations or guidelines requiring different timeframes or procedures. In 
all cases, the storage period should be aligned with participant’s consent. These additional requirements must be fo rmally communicated to, discussed and agreed with GSK or designee.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  50 of 112 8.1.1 Biological Samples  
An overall approximate volume of 15  mL per visit will be collected during the entire study 
period.  Refer to  Table 6  and Section  1.3 for details of volumes collected for different 
assessments.  
Table 6 Biological Samples  
Sample type  Quantity  Unit  Timepoint  Group 
Blood for humoral response  ~15 per visit mL Visit 1 (Day 1)  
Visit 2 (Day 31)  All participants in the  
Co-ad group  
Blood for humoral response  ~15 per visit mL Visit 1 (Day 1)  
Visit 2 (Day 31)  
Visit 3 (Day 61)  All participants in the 
Control  group  
 
The approximate volume of blood that will be collected per participant during the entire study 
period is as follows:  
• Co-ad group: 2 × ~15 mL = ~30 mL 
• Control group: 3 × ~15 mL = ~45 mL  
8.1.2 Laboratory Assays 
All laboratory testing will be performed at a GSK laboratory or in a laboratory designated by 
GSK.  
Table 7 Laboratory Assays  
Assay Type  System  Component  Method  Laboratory  
Humoral 
immunity 
(antibody determination)  Serum  RSV -A Ab  Neutralization  
GSK*  RSV -B Ab  Neutralization  
Streptococcus pneumoniae - serotype 1 Ab  
Streptococcus pneumoniae - serotype 3 Ab  
Streptococcus pneumoniae - serotype 4 Ab  
Streptococcus pneumoniae - serotype 5 Ab  
Streptococcus pneumoniae - serotype 6A Ab  
Streptococcus pneumoniae - serotype 6B Ab  
Streptococcus pneumoniae - serotype 7F Ab  
Streptococcus pneumoniae - serotype 8 Ab  
Streptococcus pneumoniae - serotype 9V Ab  
Streptococcus pneumoniae - serotype 10A Ab  
Streptococcus pneumoniae - serotype 11A Ab  
Streptococcus pneumoniae - serotype 12F Ab  Multiplexed 
Opsonophagocytosis 
Assay (MOPA) 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  52 of 112 Blood sampling timepoint  
Subset tested  N of 
participants  Component  Type of contact and timepoint  Sampling timepoint  
  All participants  545 Streptococcus pneumoniae - serotype 6B 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 7F 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 8 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 9V 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
10A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
11A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
12F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 14 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
15B Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
18C Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
19A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
19F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
22F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
23F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
33F Opsonophagocytic  Antibodies  
Visit 2 (Day 31) Post- dose 1  All participants  545 RSV -A neutralizing antibody  
  All participants  545 RSV -B neutralizing antibody   
  All participants  545 Streptococcus pneumoniae - serotype 1 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 3 
Opsonophagocytic  Antiboides  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  53 of 112 Blood sampling timepoint  
Subset tested  N of 
participants  Component  Type of contact and timepoint  Sampling timepoint  
  All participants  545 Streptococcus pneumoniae - serotype 4 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 5 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 6A 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 6B 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 7F 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 8 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 9V 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
10A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
11A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
12F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 14 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
15B Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
18C Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
19A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
19F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
22F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
23F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
33F Opsonophagocytic  Antibodies  
 
 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  55 of 112 Blood sampling timepoint  
Subset tested  N of 
participants  Component  Type of contact and timepoint  Sampling timepoint  
  All participants  545 Streptococcus pneumoniae - serotype 
23F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
33F Opsonophagocytic  Antibodies  
Visit 2 (Day  31) Post- PCV  dose All participants  545 Streptococcus pneumoniae - serotype 1 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 3 
Opsonophagocytic  Antiboides  
  All participants  545 Streptococcus pneumoniae - serotype 4 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 5 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 6A 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 6B 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 7F 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 8 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 9V 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
10A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
11A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
12F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 14 
Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
15B Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
18C Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
19A Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
19F Opsonophagocytic  Antibodies  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  56 of 112 Blood sampling timepoint  
Subset tested  N of 
participants  Component  Type of contact and timepoint  Sampling timepoint  
  All participants  545 Streptococcus pneumoniae - serotype 
22F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
23F Opsonophagocytic  Antibodies  
  All participants  545 Streptococcus pneumoniae - serotype 
33F Opsonophagocytic  Antibodies  
 Pre-RSV dose  All participants  545 RSV -A neutralizing antibody  
  All participants  545 RSV -B neutralizing antibody   
Visit 3 (Day  61) Post- RSV dose  All participants  545 RSV -A neutralizing antibody  
  All participants  545 RSV -B neutralizing antibody   
Abbreviations: N=number; RSV=respiratory syncytial virus ; PCV=pneumococcal conjugate vaccine  
8.1.4 Immunological Correlates of Protection  
No generally accepted immunological correlate of protection has been demonstrated so far for 
the antigen(s) used in the RSVPreF3 OA investigational vaccine .  
8.2 Safety Assessments  
The investigator and his/her designees are responsible for detecting, documenti ng, and 
reporting events that meet the definition of an AE or SAE. The investigator and designees are responsible for following up AEs that are serious, considered related to the study intervention  
or the study, or that caused the participant’s withdrawal from the study intervention or study. 
8.2.1 Pre-Vaccination Procedures 
8.2.1.1 Collection of Demographic Data  
Record demographic data according to local regulations such as year of birth , sex, race, and 
ethnicity will be collected on the eCRF. Collection of sex, race and ethnicity data is necessary 
to assess and monitor the diversity of the trial participants.  
*Differences in the safety and efficacy of certain medical products, including vaccines, have 
been observed in racially and ethnically distinct subgroups .
6,7,8  These differences may be 
attributable to intrinsic factors (e.g., genetics, metabolism, elimination), extrinsic facto rs (e.g., 
diet, environmental exposure, sociocultural issues), or interactions between these factors. Therefore, both geographic ancestry (race) and ethnicity will be collected for all study 
participants.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  57 of 112 8.2.1.2 Medical History  
Obtain the participant’s medical hi story by interviewing the participant and/or review of the 
participant’s medical records. Record any relevant pre-existing conditions, signs and/or 
symptoms present prior to the study intervention in the eCRF. 
8.2.1.3 Vaccination History  
Obtain the participant’s vaccination history by interviewing the participant and/or review of 
the participant’s vaccination records.  
History of following vaccine administration should be recorded in eCRF. 
• Any vaccine administered up to 1 year before study vaccine administration (if possible, with the date of vaccination) 
• PPSV administration up to 5 years before first study vaccine administration  
• PCV administration any time before study vaccine administration  
• Recombinant zoster vaccine (Shingrix) administration  any time before study vaccine 
administration  
8.2.1.4 Targeted Physical Examinations  
History  directed physical examination will be performed for each participant on Day 1. If the 
investigator determines that the participant’s health on the day of study intervention 
administration temporarily precludes dosing, the visit will be rescheduled. Refer to the 
Section  5.6 for the list of criteria for temporary delay of study intervention administration. 
Treatment of any abnormality observed during this examination has to be performed 
according to local medical practice outside this study or by referral to an appropriate health 
care provider.  
Physical examination at ea ch study visit after the study intervention administration visit, will 
be performed only if the participant/participant’s caregiver  indicates during questioning that 
there might be some underlying pathology(ies) or if deemed necessary by the investigator or delegate.  
8.2.1.5 Body Temperature  
The body temperature of each participant needs to be measured prior to any study intervention administration and recorded in the eCRF. The route for measuring temperature can be oral or axillary. If the participant has fever (fever is defined as temperature ≥38.0 °C (100.4 °F)  
regardless the location of measurement) on the day of vaccination, the vaccination visit will be rescheduled within the allowed interval for this visit.   

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  58 of 112 8.2.2 Safety Contact at 6 Months Post- Last Vaccination  
Six months after the last dose of study vaccine ( i.e., Month 6 for participants in the co-ad 
group and Month 7 for participants of the control group), each participant should be contacted 
to check if he/she has experienced any SAEs or any pIMDs since last study intervention 
administration, and to collect information on concomitant medications/vaccinations. 
Multiple formats can be proposed by the site staff to organize these contacts. This contact may 
be done via email, text message, fax , or phone call for example. The most appropriate format 
should be agreed between site staff and the study participant. 
Text messages, email , and fax may be used as a screening to check if the participant has 
anything to report. If the participant answers "Yes" for at least one of the items of interest, a 
phone call must be made  to get the details on the event(s).  
Data collected via phone calls and text messages will have to be recorded in source 
documents. E -mails and faxes can be archived in source documents. Receipt of the message 
must be confirmed by the participant or caregiver, as applicable.  
8.2.3 Clinical Safety Laboratory Tests  
No clinical safety lab oratory tests are scheduled for this study . 
8.3 Adverse Events, Serious Adverse Events, and Other Safety Reporting  
Solicited and unsolicited AEs, SAEs and other safety reporting (potential immune-mediated 
diseases [pIMDs]) are to be reported as indicated in this protocol ; Refer to  Table 1  (co-ad 
group) and Table 2  (control group). The administration site solicited AEs that will be collected 
are erythema, pain, and swelling. The systemic solicited AEs that will be collected are arthralgia, fatigue, fever, headache, and myalgia. 
Safety monitoring is specified in  Figure  1 and in the endpoints ( Section 3.0 ). 
The definitions of AEs and SAEs can be found in Appendix 3. 
Adverse events will be reported by the participant (or, when appropriate, by a caregiver). 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for 
following up on AEs that are serious, considered related to the study intervention  or study 
procedures, or that caused the participant to discontinue the study/study intervention (see 
Section  7.0). 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in Appendix 3. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  59 of 112 8.3.1 Time Period and Frequency for Collecting AE , SAE, and pIMD  Information  
All AEs (regardless of the assessment of relatedness to the study vaccines), including  all SAEs 
and all pIMDs will be collected from the first study intervention administration. All SAEs and 
all pIMDs will be collected until 6 months after the last study intervention administration at 
the timepoints specified in the SoA (Section 1.3 ). 
AEs (including SAEs and pIMDs) leading to withdrawal from the study will be collected from 
the time of the first study intervention administration until the participant is discharged from 
the study. 
In addition, SAEs assessed as related to study participation (e.g., protocol- mandated invasive 
procedures) or assessed as related to any other GSK product (non- IMP) will be recorded from 
the time a participant consents to participate in the study until the participant is discharged 
from the study . 
All AEs will be collected  in the timeframe showed in  Table 9 . 
The investigator or designee will record and immediately report all SAEs to IQVIA via the Expedited AE Reporting Form. Reporting should, under no circumstances, occur later than 
24 hours after the investigator becomes aware of an SAE, as indicated in  Appendix 3. The 
investigator will submit any updated SAE data to IQVIA within 24 hours of it being available.  

CONFIDENTIAL  219276 (RSV OA=ADJ -019) 
Amendment v1.0  
23-June-2023 62 of 112 related to the study intervention or stu
dy participation, the investigator must promptly notify 
IQVIA. 
8.3.2 Method of Detecting AEs, SAEs , and pIMDs  
Detecting an d recording of AE/SAE/pIMDs are detailed in  Appendix 3.  
The method of recording, evaluating, and assessing causality of AE and SAE and the 
procedures for completing and transmitting safety reports are provided in Appendix 3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of participants is the preferred method of acquiring information related to an AE/SAE/pIMD.  
8.3.3 Follow- up of AEs , SAEs , and pIMDs  
After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All SAEs and pIMDs as defined in Section  10.3.3.1 
will be followed until resolution, stabilization, the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). Further information on follow -up 
procedures is provided in Section 10.3.5. 
8.3.4 Regulatory Reporting Requirements for SAEs and O ther E vents  
Once an investigator (or designee) becomes aware that a study participant has experienced an 
SAE/pIMD, it must be reported to IQVIA using the required documentation and within the 
timeframes mentioned in  Table 11.  This is essential for meeting GSK legal obligations and 
ethical resp onsibilities for participant safety and the safety of a study intervention  under 
clinical investigation.  
For SAEs/pIMDs, the investigator must always provide an assessment of causality at the time of the initial report, as defined in the  Appendix 3. 
Local regulatory requirements and sponsor policy for preparation of an investigator safety report of Suspected Unexpected Serious Adverse Reactions (SUSAR) must be followed. These reports will be forwarded to investigators as necessary.  
GSK has the legal responsibility to notify local authorities/regulatory agencies about the safety of an investigational study intervention. GSK will comply with country --specific 
regulatory requirements related to safety reporting to the regulatory  authority, IRB/IEC , and 
investigators.  
Refer to  Appendix 3 fo r further details regarding the reporting of SAEs/pIMDs.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  63 of 112 An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (e.g., summary or listing of SAEs) from GSK will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
Table 11 Timeframes for Submitting SAE and Other Events Reports to IQVIA  
Type of Event  Initial Reports  Follow -up of Relevant Information on a 
Previous Report  
Timeframe  Documents  Timeframe  Documents  
SAEs 24 hours*, ‡‡ Electronic‡ Expedited 
Adverse Events Report  24 hours* Electronic‡ Expedited Adverse 
Events Report  
pIMDs  24 hours**, ‡‡  Electronic‡ Expedited 
Adverse Events Report  24 hours* Electronic‡ Expedited Adverse 
Events Report  
pIMD=potential immune -mediated disease; SAE=serious adverse events .  
* Timeframe allowed after receipt or awareness of the information by the investigator/site staff.  
**Timeframe allowed once the investigator determines th at the event meets the protocol definition of a pIMD . 
‡ Paper Expedited Adverse Events Report may be submitted in the case that the electronic Expedited Adverse 
Report system is not functioning. The paper form will be dated and signed by the investigator ( or designee).  
‡‡ The investigator will be required to confirm review of the SAE/pIMD causality by ticking the ‘reviewed’ box 
in the electronic Expedited Adverse Events Report within 72 hours of submission of the SAE/pIMD.  
8.3.5 Treatment of Adverse Events 
Any medication, vaccine or products which may explain/cause/be used to treat an SAE/pIMD should be recorded in the Expedited Adverse Event Report of the participant’s eCRF. 
8.3.6 Medical Device Deficiencies  
Medical devices are being provided for use in this study as the study intervention. To fulfill 
regulatory reporting obligations worldwide, the investigator is responsible for the detection 
and documentation of events meeting the definitions of device deficiency that occur during the 
study with such devices. 
The definition of a medical device deficiency can be found in Appendix 3. 
NOTE: Device deficiencies that lead to an AE/SAE will be reported as an AE/SAE following 
the processes outlined in  Appendix 3 of  the protocol.  
8.3.6.1 Time Period for Detecting Medical Device Deficiencies  
Medical device deficiencies will be detected, documented, and reported during all periods of the study in which the medical device is used. 
If the investigator learns of any device  deficiency at any time after a participant has been 
discharged from the study, and such a device deficiency might have led to an SAE if 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  64 of 112 appropriate action had not been taken, intervention had not occurred, or circumstances had 
been less fortunate, the investigator will promptly notify GSK . 
The method of documenting medical device deficiencies is provided in Appendix 3. 
8.3.6.2 Follow- up of Medical Device Deficiencies  
Follow-up applies to all participants, including those who discontinue study intervention. 
The investigator is responsible for ensuring that follow -up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the deficiency.  
New or updated i nformation will be recorded on the originally completed form with all 
changes signed and dated by the investigator. 
8.3.6.3 Prompt Reporting of Device Deficiencies to the Sponsor 
Device deficiencies will be reported to the Sponsor or designee within 24 hours after the 
investigator determines that the event meets the protocol definition of a medical device 
deficiency. 
The medical device deficiency report form will be sent to GSK  as described in  Appendix 3.  
GSK will be the contact fo r the receipt of device deficiency reports.  
8.3.6.4 Regulatory Reporting Requirements for Device Deficiencies  
The investigator will promptly report all device deficiencies occurring with any medical 
device provided for use in the study in order for the Sponsor to fulfill the legal responsibility 
to notify appropriate regulatory authorities and other entities about certain safety information relating to medical devices being used in clinical studies. 
The investigator, or responsible person according to local require ments ( e.g., the head of the 
medical institution), will comply with the applicable local regulatory requirements relating to 
the reporting of device deficiencies to the IRB/IEC.  
8.4 Participant Card 
The investigator (or designee) must provide the participant w ith a “participant card” 
containing information about the clinical study. The participant must be instructed to always keep the participant card in his/her/their possession for the duration of the study. In an 
emergency, this card serves to inform the resp onsible attending physician/caregiver/family 
member that the participant is in a clinical study and that relevant information may be 
obtained by contacting the investigator or his/her backup. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  65 of 112 8.5 Pharmacokinetics  
Pharmacokinetic parameters are not evaluated in this study . 
8.6 Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study.  
8.7 Genetics  
Genetics are not evaluated in this study.  
8.8 Biomarkers  
Biomarkers are not evaluated in this study.  
8.9 Immunogenicity Assessments 
Immunogenicity is described in Section 8.1. 
8.10 Health Outcomes 
Not applicable for this study. 
8.11 Health Economic s 
Health economics parameters are not eval uated in this study. 
 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  67 of 112  
9.2 Populations for Analysis  
Populations for analyses in this study are defined in Table 13. 
Table 13 Analysis Sets 
Analysis Set  Description  
Screened set  All participants who were screened for eligibility.  
Enrolled set  Participants who were randomized or received study intervention or have undergone 
an invasive procedure.  
ES All participants who received a study intervention. Analysis per group is based on the 
study intervention administered.  
PPS All eligible participants:  
• Who received all study interventions as per protocol  
• Had immunogenicity results pre - and post- dose 
• Complied with blood draw intervals (contribution of participants to PPS at specific timepoint will be defined by timepoint)  
• Without intercurrent medical conditions that may interfere with immunogenicity  
• Without prohibited concomitant medication/vaccination  
Abbreviations: ES=Exposed set; PPS=Per  Protocol set.  
9.2.1 Criteria for Elimination  
If the participant meets one of the criteria mentioned below or any listed in the Section  7.1.1, 
(contraindication to subsequent vaccination) or Section  5.2.1 (medical conditions) or 
Section  5.2.2 ( prior and concomitant therapy), he/she may be eliminated from per protocol 
analysis.  
In case of unplanned administration of any medication mentioned in Section 5.2.2 dur ing the 
study, this wi ll be considered as a protocol deviation and the participant may be eliminated 
from the Per Protocol set (PPS).  
Participants may be eliminated from the PPS for immunogenicity if, during the study, they 
incur a condition that has the capability of altering their immune response (intercurrent medical condition) or are confirmed to have an alteration of their initial immune status.  Refer 
to Glossary of Terms  for the definition of intercurrent medical conditions. 
9.3 Statistical Analyses  
The S tatistical Analysis P lan (SAP)  will be developed and finalized before f irst subject f irst 
visit (FS FV) and wil l include a more technical and detailed description of the statistical 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  68 of 112 analyses including the supportive analyses and demography summaries. This section is a 
summary of the planned statistical analyses of the primary and secondary endpoints. 
9.3.1 Primary Endpoi nt(s)/Estimand(s) Analysis 
The primary endpoints are described in Section 3.0 . The confirmatory analyses of 
non-inferiority will be based on the PPS.  
• Method for non- inferiority of the PCV20  in terms of opsonophagocytic (OP) Ab GMT 
between groups ratio for each of the pneumococcal vaccine serotypes at one month after 
the PCV20  dose (i.e., at Day 31 for both groups): 
o The 2 -sided 95% CI for Group GMT ratio between the PCV20  administered alone 
(control group) over PCV20  (co-a d group) co-- administered with the RSVPreF3 OA 
investigational vaccine will be derived from an  analysis of covariance ( ANCOVA) 
model* on log 10 transformed titer.  
• Method for non- inferiority of RSV investigational vaccine in terms of RSV -A neutralizing 
antibody geometric mean titer (GMT) between groups rat io at one after the RSVPreF3 OA 
investigational vaccine dose ( i.e., at Day 31 for the co-ad group and at Day 61 for the 
control group): 
o The 2 -sided 95% CI for RSV -A neutralizing antibody GMT ratio between RSVPreF3 
OA investigational vaccine administered alone ( control group) over RSVPreF3 OA 
investigational vaccine when co -administered with the PCV20 vaccine (co-ad group) 
will be derived from an ANCOVA model* on log 10 transformed  titer.  
• Method for non- inferiority of RSV investigational vaccine in terms of RSV -B neutralizing 
antibody geometric mean titer (GMT) between groups ratio at one after the RSVPreF3 OA 
investigational vaccine dose (i.e., at Day 31 for the co-ad group and at Day 61 for the control group): 
o The 2 -sided 95% CI for RSV -B neutralizing antibody GMT ratio between RSVPreF3 
OA investigational vaccine administered alone ( control group) over RSVPreF3 OA 
investigational vaccine when co -administered with the PCV20 vaccine (co-ad group) 
will be derived from an ANCOVA model* on log
10 transformed  titer.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  69 of 112 *The model will include the intervention /treatment group and age category (age at 
vaccination: 60 to 69, 70 to 79 or ≥80 years) as fixed effects, and the pre-dose 
log 10-transformed titer as covariate. Missing data will not be replaced. Titers below the 
assay cut -off will be replaced by half the assay cut- off; titers above the upper limit of 
quantification (ULOQ) will be replaced by the ULOQ.  
9.3.1.1 Success C riteria for Non- inferiority  and T esting sequence:  
1st Sequence : 
• The upper limi t (UL) of the 2 -sided 95% CI of the GMT ratio ( control group divided by 
co-ad group) for each individual pneumococcal conjugate serotype as measured by OPA 
is ≤2. 
AND  
• The upper limit of the 2 sided 95% CI of the GMT ratio  (control group divided by co-ad 
group) between the control group versus co-ad group for RSV-A neutralizing antibody titer one month after the RSVPreF3 OA investigational vaccine dose is ≤1.5. 
2
nd sequence:  
• The upper limit of the 2 sided 95% CI of the GMT ratio  (control group divided by co-ad 
group) between the control group versus co-ad group for RSV- B neutralizing antibody 
titer one month after the RSVPreF3 OA investigational vaccine dose is ≤1.5. 
Testing will progress in the 2nd sequence only if the 1st sequence is a success, so that no 
further adjustment of alpha is required.  
The NI margin of 2 for PCV20 is based on well documented criteria for pneumococcal vaccines which has been used for demonstrating the NI of PCV20 against PCV13.
9 The NI 
margin of 1.5 for RSV is based on Center for Biologics Evaluation and Research (CBER) feedback.  
9.3.2 Secondary Endpoint(s)/Estima
 nd(s) Analysis 
Method for evaluation of humoral immune response to RSVPreF3 OA investigational vaccine 
when co -administered with the PCV20 or administered alone  
• Mean geometric increase for within participants ratios of the post -dose titer (at 1 -month 
after the RSVPreF3 OA investigational vaccine dose) over the predose titer (at baseline) 
for RSV -A neutralizing A b titers  
• Mean geometric increase for within participants ratios of the post -dose titer (at 1 -month 
after the RSVPreF3 OA investigational vaccine dose) over the predose titer (at baseline) 
for RSV -B neutralizing Ab titers  
The other secondary endpoints, as d etailed in Section 3.0, will have descriptive analyses of 
demography, immunogenicity, and safety detailed in the SAP. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  70 of 112 9.4 Interim Analysis  
9.4.1 Sequence of Analysis  
The analyses will be performed stepwise:  
• A first analysis will be performed on all immunogenicity, reactogenicity and safety 
data available and as clean as possible, when data for at least primary and secondary 
endpoints up to Visit 2  (Day 31) (co-ad group) or Visit 3 (Day 61) (control group) are 
available for all participants. This analysis will be considered as final for those 
endpoints.  
• An End of Study analysis will include all data obtained until 6 months post-last dose.  
9.5 Sample Size Determination  
The target enrollment will be approximately 1090 participants (545 in the group receiving the RSVPreF3 OA investigational vaccine co -administered with P CV20 ( co-ad group) and 545 in 
the control group where RSVPreF3 OA investigational vaccine and PCV20 are administered in a staggered manner) to obtain at least 980 evaluable participants (490 in the co- ad group 
and 490 in the control group) for the evaluati on of the primary objectives, assuming that 
approximately 10% of the enrolled participants will not be evaluable.  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  71 of 112 Table 14 Overall power to demonstrate primary objectives: non-inferiority of the 
immunogenicity of RSVPreF3 OA investigational vaccine when co -administered 
with pneumococcal vaccine (PCV20) as compared to when administered alone- 
assuming 490 evaluable participants in each group 
Endpoint  Standard 
deviation of 
log10 
concentration  Reference ratio  Non inferiorit y 
margin  Type II error  Power  
PCV Non- inferiority* (1 -sided test with alpha=2.5%)  
GMTs Opsonophagocytic (OP) antibody (Ab)       
3 0.572  1.05 2 <0.01%  >99.99%  
7F 0.733  1.05 2 0.01%  99.99%  
19A 0.771  1.05 2 0.01%  99.99%  
5 0.782  1.05 2 0.02%  99.98%  
1 0.789  1.05 2 0.02%  99.98%  
14 0.792  1.05 2 0.02%  99.98%  
8 0.797  1.05 2 0.03%  99.97%  
33F 0.797  1.05 2 0.03%  99.97%  
9V 0.825  1.05 2 0.05%  99.95%  
10A 0.839  1.05 2 0.06%  99.94%  
11A 0.843  1.05 2 0.07%  99.93%  
19F 0.845  1.05 2 0.07%  99.93%  
6B 0.882  1.05 2 0.14%  99.86%  
4 0.902  1.05 2 0.20%  99.80%  
18C 0.910  1.05 2 0.22%  99.78%  
6A 0.927  1.05 2 0.29%  99.71%  
12F 0.943  1.05 2 0.37%  99.63%  
22F 0.966  1.05 2 0.51%  99.49%  
15B 1.088  1.05 2 1.96%  98.04%  
23F 1.096  1.05 2 2.10%  97.90%  
Global Type II error to show non -inferiority  ~6.2%   
Global power for PCV  ~93.8%  
RSV -A Non- inferiority* (1 -sided test with alpha = 2.5%)  
GMTs RSV -A neutralization 
antibody  0.45 1.05 1.5 0.04%  99.96%  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  72 of 112 Endpoint  Standard 
deviation of 
log10 concentration  Reference ratio  Non 
inferiorit y 
margin  Type II 
error  Power  
RSV -B Non -inferiority* (1 -sided test with alpha = 2.5%)  
GMTs RSV -B neutralization 
antibody  0.45 1.05 1.5 0.04%  99.96%  
Global Power for the study  ~6.28 ~93.7 
Abbreviations:  Ab=antibody; GMT=geometric mean titer; OA=older adult;  OP=opsonophagocytic; 
PCV=pneumococcal vaccine; RSV=respiratory syncytial virus.  
*Pass 2019 alpha=2.5%, Two- Sample T -Tests for Non -Inferiority Assuming Equal Variance and Equal mean, 
Power=100- the Type  II error (Beta). The Global Type II error (Beta) has b een adjusted using Bonferroni’s 
method (Global Type  II error=sum of the individual Type II errors).  
For RSV: non -inferiority limit=0.176 (=log10[1.5]).  
For each PCV vaccine strain: non -inferiority limit=0.301 (=log10[2.0]).  
Reference Ratio=0.0212 (=log10[1.05]) 
Considering a slight interference of 1.05  in true GMTs in both groups with a common 
population standard error of 0.45 for the RSV- A and RSV-B neutralizing Ab and the 
respective SD’s for each of the PCV serotype in log 10 transformed concentration, the study has 
at least 93. 7% power to meet the primary objectives.  
 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  73 of 112 10.0 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 
10.1.1 Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
international ethical guideline s 
• Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP ) 
guidelines 
• Applicable laws and regulations. 
The protocol, protocol amendments, ICF, IB , and other relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and 
approved by the IRB/IEC before the study is initiated. 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study des ign, except for changes necessary to eliminate an immediate 
hazard to study participants.  
Protocols and any substantial amendments to the protocol may require health authority 
approval prior to initiation except for changes necessary to eliminate an immed iate hazard to 
study participants. 
The investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures estab lished by 
the IRB/IEC  
• Notifying the IRB/IEC of SAEs , Device Deficiency or other significant safety findings as 
required by IRB/IEC procedures 
• Providing oversight of the conduct of the study at the study site and adherence to 
requirements of 21 Code of Fede ral Regulations (CFR), ICH guidelines, the IRB/IEC, 
European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations . 
After reading the protocol, each investigator will sign the protocol signature page and send a 
copy of the signed page to IQVIA. The study will not start at any study site  at which the 
investigator has not signed the protocol. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  74 of 112 10.1.2 Adequate Resources  
The investigator is responsible for supervising any individual or party to whom the 
investigator delegates study-related duties and functions conducted at the study site . 
If the investigator /institution retains the services of any individual or party to perform 
study- related duties and functions, the investigator/institution should ensure this individual or 
party is qualified to perform those study- related duties and functions and should implement 
procedures to ensure the integrity of the study-related duties and functions performed and any data generated.  
10.1.3 Financial Disclosure  
Investigators and sub- investigators will provide GSK or designee with sufficient, accurate 
financial information as requested to allow GSK to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigato rs 
are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study. 
10.1.4 Recruitment Arrangements and Informed Consent Process 
Recruitment Arrangements 
• Potential participants will be invited to participate in this clinical study by the study 
personnel or clinical staff (including participants’ primary health physicians) in the clinic 
and/or through advertisement in appropriate resources such as, but not limited to, printed media, Intern et, or social media.  
• Identification of potential participants can involve access to identifiable information such as medical records upon participants’ and/or caregiver’s signed authorization. Clinical center personnel will follow national standards and obey local regulations for protection of 
sensitive patient health information.  
• It is allowed that the investigator is also participant’s physician or treating clinician.  
Informed Consent Process 
• The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the participants and answer all questions regarding the 
study. 
• Potential participants must be informed that their participation  is voluntary. They will be 
required to physically sign a statement of informed consent that meets the requirements of 
21 CFR 50 , local regulations, ICH guidelines, Health Insurance Portability and 
Accountability Act requirements , privacy and data protection requirements, where 
applicable, and the IRB/IEC or study center. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  75 of 112 • The medical record must include a statement that physical informed consent was obtained 
before the participant was enrolled in the study and the date the consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF. 
• Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study.  
• A physical copy of the ICF(s) must be provided to the participant and/ or their caregiver(s).  
• The participant must provide consent by signing an ICF, which summarizes the study, 
includes a consent statement and provides documentation that the participant agrees to 
continue participating in the study.  
• Participants who are rescreened are required to sign a new ICF.  
10.1.5 Data Protection 
Participants will be assigned a unique identifier (Section 6.3.1 ) by the investigator. Any 
participant records or datasets transferred to GSK will contain only the identifier. Name and 
any other information which would identify the participant will not be transferred.  
GSK will ensure protection of the personal data of the investigator and si te staff which is 
collected within the framework of and for the purpose of the study.  
• The participant/participant’s caregiver(s) must be informed that their personal 
study-related data will be used by GSK in accordance with local data protection law. The level of disclosure must also be explained to the caregiver(s), that the participant’s data 
will be used as described in the informed consent.  
• The participant/participant’s caregiver(s) must be informed that their medical records may 
be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by GSK, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities. 
• The contract between Sponsor and study sites specifies re sponsibilities of the parties 
related data protection, including handling of data security breaches and respective communication and cooperation of the parties. 
• Information technology systems used to collect, process, and store study- related data are 
secured by technical and organizational security measures designed to protect such data against accidental or unlawful loss, alteration, or unauthorized disclosure or access. GSK and/or trusted third parties working on behalf of GSK and/or institutions working with 
GSK for the purposes of this study are contractually bound to protect participant coded 
data. GSK will protect participant coded data and will only share it as described in the ICF. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  76 of 112 The participants must be notified about their rights regarding the us e of their personal data in 
accordance with the data privacy section of the ICF.   
10.1.6 Committees Structure  
Safety oversight will be provided by a SRT composed of GSK RSV OA project team 
members. An SRT is in place for each GSK product. It comprises of a global cross -functional 
team responsible for the ongoing assessment of benefit -risk for a product. The SRT 
contributes to the continual assessment of incoming new efficacy and safety information.  
GSK will obtain favorable opinion/approval to conduct the study f rom the appropriate 
regulatory agency, in accordance with applicable regulatory requirements, prior to a site 
initiating the study in that country. This includes IRBs/IECs for review and approval of the 
protocol and subsequent amendments, ICF and any other documentation. 
10.1.7 Dissemination of Clinical Study Data  
The key design elements of this protocol and results summaries will be posted on 
www.ClinicalTrials.gov and/or GSK Clinical Study Register in compliance with applicable 
regulations/GSK policy. GSK will aim to register protocols summaries prior to study start and target results summaries submission within 12 months of primary/study completion date. Where external regulations require earlier disclosure, GSK will follow those timelines.  
Where required by regulation, summaries will also be posted on applicable national or 
regional clinical trial registers.  
Where required by applicable regulatory requirements, an investigator signatory will be identified for the approval of the study report, and provided reasonable access to statistical tables, figures, and relevant reports. GSK will also provide the investigator with the full 
summary of the study results , including a summary of trial results understandable to 
laypersons. The investigator is encouraged to share the plain language summary results with 
the study participants, as appropriate. The full study report will be made available upon 
request, after decision on marketing authorization by regulatory authorities. 
GSK will provide the investigator with the rand omization codes and participant- level line 
listings for their site only after completion of the full statistical analysis.  
GSK intends to make anonymized patient -level data from this trial available to external 
researchers for scientific analyses or to conduct further research that can help advance medical 
science or improve patient care. This helps ensure the data provided by trial participants are used to maximum effect in the creation of knowledge and understanding. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  77 of 112 10.1.8 Data Quality Assurance 
All participant data related to the study will be recorded on printed or eCRF unless transmitted 
to GSK/IQVIA  electronically (e.g., laboratory data). The investigator is responsible for 
verifying that data entries are accurate and correct by physically or electronically signing the eCRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source documents or certified copies for such review and inspection.  
GSK or designee is responsible for the data management of this study including quality 
checking of the source data (see Glossary of Terms  for the exact definition of source data).  
GSK assumes accountability for actions delegated to other individuals (e.g., C ontract 
Research Organizations). 
Quality tolerance limits (QTLs) will be pre -defined in the state location(s) to identify 
systematic issues that can impact participant safety and/or the reliability of study results. These pre -defined parameters will be monitored during the study. Important deviations from 
the QTLs and remedial actions taken will be summarized in the Clinical Study Report (CSR).  
Monitoring details describing strategy, including definition of study critical data items and processes (e.g., risk -based initiatives in operations and quality such as risk management and 
mitigation strategies and analytical risk -based monitoring, involvement of central reading 
mechanism) methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on -site monitoring) are 
provided in the  monitoring plan. 
The sponsor or designee is responsible for the data management of this study, including quality checking of the data. 
Records and source documents pertaining to the conduct of this study, including signed ICFs, 
must be retained by the investigator for 25 years from issuance of the final CSR/equivalent summary  unless local regulations or institutional policies require a longer retention period. No 
records may be destroyed during the retention period without the written approval of GSK . No 
records may be transferred to another location or party without written notification to GSK.  
10.1.9 Source Documents  
The investigator/institution should maintain adequate and accurate source documents and 
study records that include all pertinent observations on each of the study site’s participants. 
Source data should be attributable, legible, contemporaneous, original, accurate, and 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  78 of 112 complete. Changes to source data should be traceable, should not obscure the original entry, 
and should be explained if necessary (e.g., via an audit trail).  
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available. 
Definition of what constitutes source data and its origin can be found in Glossary of Terms .  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by authorized study site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements. 
10.1.10 Study and Site Start and Closure  
First Act of Recruitment  
The start of study and the first act of recruitment are defined as first subject first visit (first 
ICF signature date) at a country -level.   
Study/Site Termination  
GSK or its designee reserves the right to close the study site or terminate the study at any time for any reason at its sole discretion, provided there is sufficient notice given to account for all partici pants safe exit from study.  
Regular closure of study sites will occur upon study completion. A study site is considered closed when all required data/documents and study supplies have been collected and a study site closure visit has been performed.  
The investigator may initiate study  site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  79 of 112 Reasons for the early closure of a study site by GSK  or investigator may include but are not 
limited to:  
For study termination: 
• Discontinuation of further study intervention development. 
For study site termination: • Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, GSK’s procedures, or GCP guidelines 
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of participants 
by the inve stigator  
• Discontinuation of further study intervention development 
• Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, GSK shall promptly inform the 
investigators, the IECs/IRBs, the regulatory a uthorities, and any Contract R esearch 
Organization(s) used in the study of the reason for termination or suspension, as specified by 
the applicable regulatory requirements. The i nvestigator shall promptly inform the participant 
and should assure appropriat e participant therapy and/or follow -up. 
10.1.11 Publication Policy  
The results of this study may be published in peer reviewed scientific literature and/or presented at scientific meetings. The sponsor will comply with the requirements for 
publication of study res ults in accordance with standard editorial and ethical practice and as 
per the sponsor’s internal policy. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.  
  

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  80 of 112 10.2 Appe ndix 2: Clinical Laboratory Tests 
RSV -A and RSV -B neutralization assays  
The serum neutralization assay is a functional assay that measures the ability of serum 
antibodies to neutralize RSV entry and replication in a host cell line.  
Virus neutralization is performed by incubating a fixed amount of RSV-A strain (Long, ATCC No. VR-26) or RSV-B strain (18537, ATCC No. VR- 1580) with serial dilutions of the 
test serum. The serum -virus mixture is then transferred onto a Vero cells culture (Africa n 
Green Monkey, kidney, Cercopitheus aethiops, ATCC CCL 81) and incubated for 2 days to allow infection of the Vero cells by non-neutralized virus and the formation of plaques in the cell monolayer. Following a fixation step, RSV- infected cells are detected using a primary 
antibody directed against RSV (Polyclonal anti- RSV-A/B IgG) and a secondary antibody 
conjugated to horse-radish peroxidase (HRP), allowing the visualization of plaques after coloration with TrueBlue peroxidase substrate.  
Viral plaques are  counted using an automated microscope coupled to an image analyzer 
(Scanlab system with a Reading software or equivalent). For each serum dilution, a ratio, expressed as a percentage, is calculated between the number of plaques at each serum dilution 
and the number of plaques in the virus control wells (no serum added). The serum neutralizing 
antibody titer is expressed in Estimated Dilution 60 (ED60) and corresponds to the inverse of the interpolated serum dilution that yields a 60% reduction in the numbe r of plaques compared 
to the virus control wells, as described by others .
10,11 For the testing of Phase III studies, 
secondary standards calibrated against the international reference12,13 will be included in every 
run to allow conversion into international units. 
 

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  85 of 112 • Any device deficiency that might have led to an SAE if appropriate action had not been taken, 
interve ntion had not occurred, or circumstances had been less fortunate. 
10.3.3 Adverse Events of Special Interest  
Potential immune- mediated diseases are the only adverse events of special interest ( AESIs ) 
collected during this study.  
10.3.3.1 Potential Immune -Mediated Diseases  
Potential immune- mediated disease is a subset of AESIs that include autoimmune diseases 
and other inflammatory and/or neurologic disorders of interest which may or may not have an 
autoimmune etiology. AEs that need to be recorded and reported as pIMDs include those 
listed in the  Table 17.  Please refer to the Appendix 3 fo r reporting details.  
The i nvestigator must exercise his/her medical/scientific judgment to determine whether other 
diseases have an autoimmune origin ( i.e., pathophysiology involving systemic or 
organ- specific pathogenic autoantibodies) and should also be recorded as a pIMD.  In addition, 
the investigator should categorize each pIMD either as a new onset condition (if it started 
following vaccination) or as an exacerbation of a preexisting chronic condition (if it 
exacerbated following vaccination) in the eCRF.  In order to facilitate  the documentation of 
pIMDs in the eCRF, a pIMD standard questionnaire and a list of preferred terms (PTs) and PT codes corresponding to the above diagnoses will be available to investigators at study start.

CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023   91 of 112 Medical Concept  Additional Notes  
Idiopathic cranial nerve palsies/paresis and 
inflammations (neuritis)  Including but not limited to:  
• Cranial nerve neuritis (e.g., Optic neuritis)  
• Idiopathic nerve palsies/paresis (e.g., Bell’s palsy)  
• Melkersson -Rosenthal syndrome  
• Multiple cranial nerve palsies/paresis  
Multiple sclerosis (MS)  Includes the following:  
• Clinically isolated syndrome (CIS)  
• Malignant MS (the Marburg type of MS)  
• Primary -progressive MS (PPMS)  
• Radiologically isolated syndrome (RIS)  
• Relapsing -remitting MS (RRMS)  
• Secondary -progressive MS (SPMS)  
• Uhthoff's phenomenon  
Mya sthenia gravis  Includes ocular myasthenia and Lambert -Eaton myasthenic syndrome  
Narcolepsy  Includes narcolepsy with or without presence of unambiguous cataplexy  
Peripheral inflammatory demyelinating neuropathies and plexopathies  Including but not limited to:  
• Acute Brachial Radiculitis (also known as Parsonage- Turner Syndrome or neuralgic amyotrophy) 
• Antibody- mediated demyelinating neuropathy  
• Chronic idiopathic axonal polyneuropathy (CIAP)  
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy (C IDP), including atypical CIDP 
variants (e.g., multifocal acquired demyelinating sensory and motor neuropathy also known as 
Lewis -Sumner syndrome) 
• Multifocal motor neuropathy (MMN)  
Transverse myelitis (TM)  Includes acute partial transverse myelitis (APTM) and acute complete transverse myelitis (ACTM)  
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023   95 of 112 Medical Concept  Additional Notes  
Multisystem inflammatory syndromes  Including but not limited to:  
• Kawasaki’s disease 
• Multisystem inflammatory syndrome in adults (MIS -A) 
• Multisystem inflammatory syndrome in children (MIS -C)  
Overlap syndrome   
Raynaud’s phenomenon   
Sarcoidosis  Includes Loefgren syndrome  
Susac's syndrome   
 
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  97 of 112 • Data on solicited events reported in the eDiary will be electronically transferred to the eDiary 
vendor, where it can be monitored by appropriately qualified site staff and sponsor staff 
through a web-based portal. Appropriately qualified site staff should monitor eDiary data online at frequent intervals for subject compliance and reported events that were of concern to the subject.  
• Refer to the eDiary Manual for more information regarding the use of eDiary.  
• For device deficiencies, it is very important that the investigator describes any corrective or remedial actions taken to prevent recurrence of the deficiency.  
o A remedial action is any action other than routine maintenance or servicing of a medical device where such action is necessary to prevent recurrence of a device deficiency. This includes any amendment to the device design to prevent recurrence.  
• If the site during the course of the study becomes aware of an y serious, nonserious incident 
(including device deficiencies and malfunctions) related to any GSK non-IMP product they 
will report these events to GSK or to the concerned competent authority via the national 
spontaneous reporting system.  
10.3.5.1 Time Period for Collecting and Recording AEs, SAEs, and pIMDs 
Time Period for Collecting and Recording AEs, SAEs, and pIMDs  
• All solicited events that occur during 7 days following administration of the dose of study 
intervention (Day 1 to Day 7 ) must be recorded into the eDiary, irrespective of intensity. All 
other AEs occurring within this time frame should be recorded onto/into the appropriate section of the eCRF, i rrespective of their intensity or whether or not they are considered related to the 
study intervention.  
• All unsolicited  AEs that occur during 30 days following administration of each dose/the dose of 
study intervention must be recorded onto/into the appropriate section of the eCRF, irrespective of their intensity or whether or not they are considered related to the study intervention.  
• All SAEs, and pIMDs that occur up to 6 months post last -dose of study intervention must be 
recorded onto/into the appropriat e section of the eCRF, irrespective of their intensity or whether 
or not they are considered related to the study intervention.  
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  103 of 112  
10.4 Appendix 4: Abbreviations and Glossary of Terms 
 
Table 19 Abbreviations List  
Abbreviation  Definition  
Ab Antibody  
AE Adverse event  
AESI  Adverse event of special interest  
ANCOVA  Analysis of Covariance  
C Celsius  
CBER  Center for Biologics Evaluation and Research  
CD4  Cluster of Differentiation 4  
CFR  Code of Federal Regulations  
CI Confidence interval  
CMI  Cell-mediated immunity  
Co-ad Co-administration group  
COVID -19 Coronavirus disease 2019  
CSR  Clinical Study Report  
CTR  Clinical Trial Regulation  
eCRF  Electronic case report form  
DTaP  Diphtheria -tetanus -pertussis  
EEC  European Economic Community  
EoS End of Study  
EU European Union  
F Fahrenheit  
FSFV First subject  first visit  
GCP  Good Clinical Practice  
GMT  Geometric mean titer  
GSK  GlaxoSmithKline  
HCP  Health care professional  
IB Investigator’s Brochure  
ICF Informed Consent Form  
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  104 of 112 Abbreviation  Definition  
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use 
ID Identification  
IEC Independent Ethics Committee  
IMP Investigational medicinal product  
IRB Institutional Review Board  
IWRS  Interactive Web Response System  
LSLV Last subject  last visit  
MedDRA  Medical Dictionary for Regulatory Activities  
MGI  Mean geometric increase  
MMSE  Mini -Mental State Examination  
MoCA  Montreal Cognitive Assessment  
MOP A Multiplexed Opsonophagocytosis  
OA Older adult  
OP Opsonophagocytic  
PCV  Pneumococcal Conjugate Vaccine  
pIMD  Potential  Immune -Medi cated Disease  
PPS Per Protocol Set  
PPSV  Pneumococcal polysaccharide vaccine  
RSV  Respiratory syncytial virus  
SADE  Serious adverse device effect  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SAR  Serious adverse reaction  
SoA Schedule of activities  
SRM  Study Reference Manual  
SRT Safety Review Team  
ST Serotype  
SUSAR  Suspected Unexpected Serious Adverse Reactions  
UADE  Unanticipated adverse device effect  
UL Upper limit  
YOA  Years of age  
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  105 of 112 Table 20 Glossary of Terms  
Adverse event:  Any untoward medical occurrence in a patient or clinical 
investigation participant, temporally associated with the use 
of a medicinal product, whe ther or not considered related to 
the medicinal product.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with 
the use of a medicinal product. For marketed medicinal 
products, this also includes failure to produce expected benefits ( i.e., lack of efficacy), abuse or misuse.  
Blinding:  A procedure in which 1 or more parties to the trial are kept 
unaware of the intervention assignment in order to reduce the risk of biased study outcomes. The level of blinding is 
maintained throughout the conduct of the trial, and only 
when the data are cl eaned to an acceptable level of quality 
will appropriate personnel be unblinded or when required in case of a serious AEs  
In an open-label study, no blind is used. Both the investigator and the participant know the identity of the intervention assigned.  
Caregiver:  A ‘caregiver’ is a person who has a continuous caring role 
for a participant or may be a person having substantial 
periods of contact with a participant and/or is engaged in 
his/her daily health care ( e.g., a relative of the participant 
including family members or friends).  
In the context of this study, a caregiver can be appointed by the participant to oversee and support the participant’s compliance with protocol -specific procedures (such as 
transcribing responses to diaries, receiving phone calls, planning study visits, etc.). However, at no time, the caregiver should evaluate the participant’s health status 
while answering diaries or make decisions on behalf of the 
participant.  
Eligible:  Qualified for en rollment into the study based upon strict 
adherence to inclusion/exclusion criteria. 
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  106 of 112 Enrolled participant:  ‘Enrolled’ means a participant’s agreement to participate in 
a clinical study following completion of the informed 
consent process. Potential partic ipants who are screened for 
determining eligibility for the study, but do not participate 
in the study, are not considered enrolled, unless otherwise specified by the protocol.  
Refer to the  Section 9.2 of the protocol for the definition of 
‘enrolled set’ applicable to the study.  
Evaluable:  Meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and, therefore, included in the per- protocol analysis.  
Immunological correlate of 
protection:  A correlate of risk that has been validated to predict a 
certain level of protection from the targeted endpoint. 
Intercurrent medical 
condition:  A condition that has the capability of altering the immune 
response to the study vaccine or is confirmed to have an alteration of the participant’s initial immune status.  
Intervention number:  A number identifying an intervention to a participant, 
according to intervention allocation. 
Intervention:  Term used throughout the clinical study to denote a set of 
investigational product(s) or marketed product(s) or placebo intended to be administered to a participant. 
Investigational vaccine:  A pharmaceutical form of an active ingredien t being tested 
in a clinical trial, including a product with a marketing 
authorization when used in a way different from the 
approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.  
Synonym: Investigational Medicinal Product.  
Investigator:  A person responsible for the conduct of the clinical trial at a 
trial site. If a trial is conducted by a team of individuals at a trial site, the investigator is the responsible leader of the team and may be called the principal investigator.  
The investigator can delegate trial -related duties and 
functions conducted at the trial site to qualified individual or party to perform those trial-related duties and functions. 
Participant:  Term used throughout the  protocol to denote an individual 
who has been contacted to participate or who participates in 
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  107 of 112 the clinical study as a recipient of the study intervention 
(vaccine(s)/product(s)/control).  
Synonym: subject. 
Randomization:  Process of random attribution of i ntervention to participants 
to reduce selection bias.  
Remote visit  This term refers to the visit conducted in the place other 
than the study site. 
Serious Adverse Reaction  All noxious and unintended responses to an IMP related to 
any dose administered that result in death, are life -
threatening, require patient hospitalization or prolongation 
of existing hospitalization, result in persistent or significant 
disability or incapacity, or are a congenital anomaly or birth 
defect.   
Source data:  All information in original records and certified copies of 
original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source docum ents (original records or certified copies).  
Source documents:  Original legible documents, data, and records (eg, hospital 
records, clinical and office charts, laboratory notes, 
memoranda, participants' diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified 
after verification as being accurate copies, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, participant files, and records kept at the pharma cy, 
laboratories and at medico- technical departments involved 
in the clinical trial).  
Study intervention:  Any investigational or marketed product(s) or placebo 
intended to be administered to a participant during the study. 
Suspected Unexpected 
Serious Adverse Reaction  A Suspected Unexpected Serious Adverse Reaction is a 
Serious Adverse Reaction whose nature, severity or outcome is not consistent with the reference safety information. 
Telemedicine  The use of electronic information and telecommun ications 
technologies (both video -based and audio -only) to facilitate 
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  108 of 112 remote health care delivery, participant and professional 
health -related education, public health and health 
administration.  
Unsolicited adverse event:  Any AE reported in addition to th ose solicited during the 
clinical study. Also, any ‘solicited’ symptom with onset 
outside the specified period of follow- up for solicited 
symptoms will be reported as an unsolicited adverse event.  
Virtual visit  This term refers to study visits conducted u sing multimedia 
or technological platforms.  
 
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  109 of 112 10.5 Appendix 5: Protocol Amendment History 
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the table of contents. 
This amendment is considered to be nonsubstanti al based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European 
Union because it neither significantly impacts the safety or physical/mental integrity of 
participants nor the scientific  value of the study. 
Overall Rationale for Protocol Update:  
The Original Protocol is updated to version 2.0 to clarify the timeframe to collect adverse events, serious adverse events, and pIMDs in Appendix 3 of this document. Additionally, the Protocol Investigator Agreement has been added to this document. During this protocol update minor clarifications were added.  
(Added text is bold italic ,
  deleted text is strikethrough ) 
Section # and Name  Description of Change  Brief Rationale  
Protocol Investigator 
Agreement  Added to the page after the Sponsor Signatory page.  Included to avoid separate collection of signed Protocol Investigator Agreement.  
Sponsor signatory page  Updated signatory:  
Mathieu Peeters, MD  
Maria Van Der Wielen, MD  Original signatory on leave.  
1.1 Synopsis  Edited text: 
Data Monitoring Committee/Other 
Committee: None  
Safety monitoring:  the study will 
be conducted with oversight by the 
project Safety Review Team.  Clarification  
1.3 Schema  Edited text: 
AEs/SAEs leading to withdrawal 
from the study start up to study 
end Clarification  
2.3.1 Risk Assessment  Added text to RSV investigational 
vaccine Mitigation Strategy: 
Participants with a history of 
hypersensitivity or severe allergic reaction to any component of the 
vaccine are excluded from study 
enrollment.  Additional mitigation strategy for known hypersensitivity or severe allergic reaction.  
5.2.2 Prior and Concomitant Therapy  Deleted bullet: 
• Administration of long -actin
 g 
immune -modifying drugs or 
planned administration at any To minimize the interference due to external factors among study participants.  
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  110 of 112 Section # and Name  Description of Change  Brief Rationale  
time during the study period 
(e.g., infliximab).  
Added bullet:  
• Administration of long -acting 
immune -modifying drugs 
during the period starting 
180 days before the 
adminis tration of first dose of 
study interventions or planned administration at any time during the study period (e.g., infliximab).  
 
5.6 Criteria for Temporarily Delaying  Added bullet:  
• Use of antipyretics and/or 
analgesics and/or antibiotics 
within 3 days prior to study intervention administration.  Use of antipyretics and/or analgesics and/or antibiotics within 3 days may indicate an acute condition.  
6.1 Study Interventions Administered  Edited text:  
Vial; suspension  for suspension  
for injection  Clarification  
6.6 Treatment of Overdose  Added section To better guide investigators about what to do in case of an overdose.  
7.1 Discontinuation of 
Study Intervention  Edited text: 
Adverse event requiring expedited report i 
ng to IQVIA  GSK  Clarification  
10.3.5.1 Time Period for 
Collecting and Recording 
AEs, SAEs, and pIMDs  Edited text:  
•All unsolicited  AEs that occur 
during 30 days following administration of each dose/the 
dose of study intervention must be 
recorded onto/into the appropriate section of the eCRF (…)  
 
Added text:  
•All SAEs, and pIMDs that occur 
up to 6 months post last -dose of 
study inter vention must be 
recorded onto/into the appropriate 
section of the eCRF, irrespective 
of their intensity or whether or not they are considered related to the study intervention.  Clarification on timing of AE, SAE, and pIMD collection for this study.  
Summar y of Changes  Summary of Changes table was added to document updates to Original Protocol.  Version control 
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  111 of 112 11.0 REFERENCES 
1. Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other 
respiratory viral infections in older adults with moderate to severe influenza- like 
illness. J Infect Dis., 2014; 209(12):1873-81. doi: 10.1093/infdis/jit839. 
2. Shi T, Denouel A, Tiejen AK, et al. Global Disease Burden Estimates of Respiratory Syncytial Virus- Associated Acute Respiratory Infection in Older Adults in  2015: A 
Systematic Review and Meta-Analysis. The Journal od Infectious Diseases. 2019;222(Supplement_7):S577-S583.doi:10.1093/infdis/jiz059. 
3. Dowell  SF, Whitney CG, Wright C, et al. Seasonal patterns of invasive pneumococcal 
disease. Emerg Infect Dis. , 2003; 9(5):573-9. doi: 10.3201/eid0905.020556. 
4. Weinberger DM, Harboe ZB, Viboud C, et al. Pneumococcal disease seasonality: incidence, severity and the role of influenza activity. Eur Respir J.  2014; 43(3):833-41. 
doi: 10.1183/09031936.00056813. 
5. GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% 
reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial  
(2022). GSK. Available at: https://www.gsk.com/en- gb/media/press -releases/gsk -s-
older-adult- respiratory -syncytial- virus -rsv-vaccine- candidate/ (Accessed: December 8, 
2022).  
6. Borchers AT, Chang C, Gershwin ME, et al.  Respiratory syncytial virus – a 
comprehensive review. Clin Rev Allergy Immunol. 2013;45:331-79. 
7. Pérez- Losada M, Posada D, Arenas M, et al. Ethnic differences in the adaptation rate 
of HIV gp120 from a vaccine trial. Retrovirology. 2009; 6:67. 
8. Kollmann TR. Variation between Populations in the Innate Immune Response to Vaccine Adjuvants. Front Immunol. 2013; 4:81. 
9. Essink B, Sabharwal C, Cannon K, et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Im munogenicity of 20-Valent Pneumococcal Conjugate 
Vaccine in Adults Aged ≥18 Years. Clin Infect Dis ., 2022; 75(3):390 -398. doi: 
10.1093/cid/ciab990. 
10. Barbas CF, Crowe JE, Cababa D, et al. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci USA. 1992; 89(21):10164-8. 
11. Bates JT, Keefer CJ, Slaughter JC, et al. Escape from neutralization by the respiratory syncytial virus- specific neutralizing monoclo nal antibody palivizumab is driven by 
changes in on-rate of binding to the fusion protein. Virology. 2014; 454-455: 139-44. 
12. McDonald JU, Rigsby P, Dougall T, et al. Establishment of the first WHO International Standard for antiserum to Respiratory Syncytical Virus: Report of an International collaborative study. Vaccine.2018; 36: 7641-7649.  
13. McDonald JU, Rigsby P, Atkinson E, et al. Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study. Vaccine. 2020; 38: 800-807. 
CONFIDENTIAL   219276 (RSV OA=ADJ -019) 
Amendment v1.0  
 
 23-June-2023  112 of 112 Signature of Investigator 
PROTOCOL TITLE: A Phase III, open -label, randomized, controlled, multi- country study to 
evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational 
vaccine when co -administered with 20 valent pneumococcal conjugate vaccine (PCV20) in 
adults aged 60 years and older.   
PROTOCOL NO:  219276 
VERSION:   Amendment v1.0  
This protocol is a confidential communication of GSK. I confirm that I have read this 
protocol, I understand it, and I will work according to this protocol. I will also work 
consistently with the ethical principles that have their origin in the Declaration of Helsinki and 
that are consistent with G ood Clinical Practices and the applicable laws and regulations. 
Acceptance of this document constitutes my agreement that no unpublished information 
contained herein will be published or disclosed without prior written approval from GSK. 
Instructions to th e investigator : Please SIGN and DATE this signature page. PRINT your name, title, and the name of the 
study center in which the study will be conducted. Return the signed copy to IQVIA.  
 
I have read this protocol in its entirety and agree to conduct the study accordingly: 
 Signature of Investigator:      ___________________________            Date:  ________ 
Printed Name:                         ___________________________ 
Investigator Title:                    ___________________________  
Name/Address of  Center:               ___________________________ 
     ___________________________ 
     ___________________________ 
 
 